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Some recently described pentapeptides containing the α,α-disubstituted α-amino acids 
Aib and Phe(2Me) have been cyclized in DMF solution using DPPA, TBTU/HOBt, and 
DEPC, respectively, to give the corresponding cyclopentapeptides in fair to good yields. In 
the case of peptides with L-amino acids and (R)- and (S)-Phe(2Me), respectively, the yields 
differed significantly in favor of the L/R combination. The conformations in the crystals of 
cyclo(Gly-Aib-(R,S)-Phe(2Me)-Aib-Gly) and cyclo(Gly-(R)-Phe(2Me)-Pro-Aib-Gly) have 
been determined by X-ray crystallography, leading to quite different results. In the latter case, 
the conformation in solution has been elucidated on the basis of NMR studies. 
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1. Introduction. – The interest in cyclic peptides reaches back to the 1940s, when 
Synge and co-workers established the structure of gramicidin S, cyclo[(Leu-D-Phe-Pro-Val-
Orn)2], a natural cyclic decapeptide with antibiotic activity [1]. Its chemical synthesis was 
achieved in 1957 by Schwyzer and Sieber [2]. Since, this class of compounds has been of 
continuing interest because of the diverse biological activities [3]. Well-known examples are 
the cyclic undecapeptide cyclosporine A, an immunosuppressant [4], the cyclodecapeptide 
gramicidin S with antibiotic properties [5], the glycopeptide vancomycin as an antibacterial 
agent used against multiresistent bacteria [6], the neuropeptide oxytocin, which acts as a 
neurotransmitter as well as a hormone [7], etc. Another aspect of the pharmacological interest 
in cyclopeptides is their higher resistance against exoproteases, resulting in a higher in vivo 
stability in comparison with linear analogues [8]. 
The most demanding step in the synthesis of cyclopeptides is the cyclization of the 
linear precursor [9]. The conditions for successful ring closures of peptides, i.e. the 
lactamization, have been known for a long time [10]. For example, the C-terminus of a N-
deprotected linear peptide has to be activated by a suitable coupling reagent or as an activated 
ester, and the principle of high dilution (10–3 – 10–5 M) has to be followed. Furthermore, 
efficient protocols for ‘solid-phase cyclization’ have been developed (e.g. [11]). 
The efficiency of the cyclization depends, beside the ring size, on a series of factors 
such as kind and configuration of the amino acids, conformation of the peptide bonds as well 
as of the peptide backbone, and also the site of the ring closure. A classical example is the 
synthesis of the cyclohexapeptide cyclo(Phe-Pro-D-Phe-Pro-Phe-Pro) via ring-closure of 
different linear precursors by treatment with diphenyl phosporazidate (DPPA) [12]. Whereas 
the cyclization of H-D-Phe-Pro-(Phe-Pro)2-OH gave the desired cyclohexapeptide in 57% 
yield, the isomeric linear precursors H-Phe-Pro-D-Phe-Pro-Phe-Pro-OH and H-(Phe-Pro)2-D-
Phe-Pro-OH, under identical conditions, led to the product in 2.4 and 0.8% yield, 
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respectively. It is important to note that the presence of one D-amino acid at the N-terminus is 
crucial for efficient ring closure. This was demonstrated by the cyclizations of H-(Phe-Pro)3-
OH and H-D-Ala-Pro-(Phe-Pro)2-OH, which led to the corresponding cyclopeptides in 2 and 
76% yield, respectively. A similar study was performed for the synthesis of the chlamydocin 
analogue cyclo-(Phe-D-Pro-Ala-Aib) (1, Scheme 1) [13]: whereas the cyclization of the N-
hydroxysuccinimide ester of the tetrapeptide TFA.H-Ala-Aib-Phe-D-Pro-OSu in pyridine led 
to the cyclotetrapeptide 1 in 44% yield, the analogous cyclizations of the other three possible 
precursors gave 1 in only 2–3% yield. 
 
Scheme 1 
 
In the case of small cyclopeptides, a major problem is the cyclodimerization [10][14]. 
For example, the cyclization of the tetrapeptide H-Gly-Phe(2Me)-Aib-Gly-OH by treatment 
with DPPA in DMF (10–3 M) led to a 1:2 mixture of the cyclic monomer and dimer [14c]. On 
the other hand, the synthesis of cyclotetrapeptides without formation of dimers as side 
products was achieved via a solid-phase protocol [15]. Also in the cyclization of 
pentapeptides, a significant tendency to dimerization has been shown. This was a major issue 
in the synthesis of gramicidin S as the desired cyclodimer [2][16]. Waki and Izumiya 
demonstrated that the ratio of monomeric and dimeric cyclopeptide depends strongly on the 
bulkiness of the N-terminal amino acid [17]. Whereas, e.g., in the case of the cyclization of 
the 4-nitrophenyl ester H-Val-Orn(δ-Z)-Leu-D-Phe-Pro-O(4-Np) the ratio was 32:78, the 
cyclization of the corresponding H-Gly-Orn(δ-Z)-Leu-D-Phe-Pro-O(4-Np) gave exclusively 
the cyclic monomer (ratio 100:0). Although to a lower extent, the steric hindrance of the C-
terminus is also of importance: the cyclization of H-Val-Orn(δ-Z)-Leu-D-Phe-Gly-O(4-Np) 
led to the cyclic monomer and dimer in a ratio of 79:21. Based on these results, Kondo et al. 
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tried to prepare the gramicidin S analogue containing Aib instead of Val via the 
cyclodimerization strategy [18]. Surprisingly, despite the sterically unfavourable situation, 
only the cyclopentapeptide cyclo(Aib-Orn(δ-Z)-Leu-D-Phe-Pro) was obtained. 
A few natural cyclopeptides containing Aib are known, i.e., the tetrapeptide 
chlamydocin and some analogues and the heptapeptides scytalidamide A and B [19]. Because 
of the β-turn- and helix-inducing properties of Aib, a series of Aib-containing cyclopeptides 
has been synthesized and their structures in the crystal as well as in solution were established 
[20]. In contrast, corresponding results for Aib-containing cyclopentapeptides are rare. For 
example, the pentapeptide TFA-salt 2 was cyclized by treatment with EtN(iPr)2 and 
(benzotriazol-1-yl)-N,N,N’,N’-bis(tetramethylene)uronium hexafluorophosphate (HBPyU) 
[20b], and the structure of the product 3 was determined by NMR methods and X-ray 
crystallography [21] (Scheme 2). In our group, the pentapeptide 4 was prepared via the 
‘azirine/oxazolone method’ [22], and ring closure to give 5 was achieved by treatment with 
DPPA [14c]. On the other hand, various syntheses of cyclopentapeptides are known (e.g. 
[23]), and the current interest in natural and biologically active cyclopentapeptides is 
remarkable (e.g. [24]).  
 
Scheme 2 
 
In the last three decades, we have elaborated the ‘azirine/oxazolone method’ for the 
synthesis of peptides containing α,α-disubstituted α-amino acids. We have also shown that 
these peptides with helical conformations can be cyclized in solution to give the 
corresponding cyclotetra-, penta-, hexa-, hepta-, and octapeptides [14c][25]. Whereas the 
cyclopenta- to octapeptides were formed as monomers exclusively, a mixture of monomer 
and dimer was formed in the case of a tetrapeptide, and only the dimer, i.e. a 
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cyclohexapeptide, was obtained from a tripeptide [14c]. Recently, we have published the 
synthesis and crystal structures of Z-protected Aib- and Phe(2Me)-containing pentapeptides 
[26]. In the present study, their cyclization to yield cyclopentapeptides is described. 
 
2. Results and Discussion. – 2.1. Cyclization of Aib- and Phe(2Me)-Containing 
Pentapeptides. – The protected pentapeptides of type 6, prepared via a combination of the 
‘azirine/oxazolone method’ and peptide coupling [26], were deprotected at the N- as well as at 
the C-terminus. For example, the ester group of Z-Gly-Aib-(R,S)-Phe(2Me)-Aib-Gly-OMe 
(6a) in MeOH was saponified by treatment with aqueous 2N NaOH at room temperature to 
give the Z-protected peptide acid in 85% yield. Hydrogenolysis of the latter (H2, Pd/C) in 
MeOH at room temperature led to the pentapeptide 4b in 86% yield (Scheme 3, Table 1). 
 
Scheme 3 
 
Alternatively, the hydrolysis of the methyl ester of pentapeptides, e.g. Z-Gly-(S)-
Phe(2Me)-Gly-Aib-Phe-OMe ((S)-6d’), was carried out with LiOH in a mixture of 
THF/MeOH/H2O (3:1:1) at 0° [27]. The pentapeptides with a terminal Aib-N(Me)Ph unit 
resulting from the coupling with 2,2,N-trimethyl-N-phenyl-2H-azirin-3-amine were 
transformed into the Z-pentapeptide acids by treatment with 3N HCl in THF/H2O (1:1), i.e. 
under the conditions of the selective amide hydrolysis [22a–d]. For example, the hydrolysis of 
Z-Gly-(R,S)-Phe(2Me)-Gly-Aib-Aib-N(Me)Ph (6c) gave the corresponding Z-pentapeptide 
acid in 98% yield.  
 
Table 1. Linear Phe(2Me) and Aib-Containing Pentapeptides 
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The deprotection of the NH2 group of the pentapeptide acids was achieved either by 
classic hydrogenolysis with H2 and ca. 10% Pd/C in MeOH at room temperature (ca. 15 h) or 
via ‘transfer hydrogenolysis’ [28] with HCO2NH4 and Pd/C in boiling MeOH (ca. 10 min). In 
general, the reactions proceeded to completeness, and the deprotected pentapeptides were 
obtained in high yields (91–100%), but in the case of 4b and (S)-4f, only 86% of the peptide 
could be isolated 2). 
For the cyclization of peptides in solution, DPPA [29a] as well as diethyl 
phosphorocyanidate (DEPC) [29b] proved to be suitable coupling reagents [12][14c][25a–d]. 
Furthermore, Jung, Kessler and coworkers showed that the cyclization of hexapeptides with 
O-(1H-benzotriazol-1-yl)-N,N,N’,N’-tetramethyluronium tetrafluoroborate (TBTU) in the 
presence of 1-hydroxybenzotriazole (HOBt) and diisopropylethylamine (DIEA) in DMF at 
room temperature proceed smoothly leading to the cylcopeptides in high yields [30].  
Based on these results, the pentapeptide 4b in DMF was cyclized by treatment with 
DPPA/NaHCO3 as well as with TBTU/HOBt/DIEA. In the first case, a solution of 1.5 equiv. 
of DPPA in DMF was slowly added to a ca. 1.6×10–3 M solution of 4b in DMF, followed by 
NaHCO3. After stirring for 63 h at 0° and purification by HPLC, pure 5b was isolated in 45% 
yield (Table 2). The analogous cyclization of a 1.1×10–3 M solution of 4b in DMF with 3 
equiv. of TBTU and HOBt and 1% DIEA for 3 h at room temperature and HPLC purification, 
gave 64% of 5b (Scheme 3). 
 
Table 2. Cyclization of Pentapeptides 4 leading to Cyclopentapeptides 5 
2)  Surprisingly, during the workup of (S)-4d, a sparingly soluble portion precipitated first 
((S)-4d’) followed by a much more soluble second portion ((S)-4d”). Although the m.p. 
and the spectroscopic data of the two materials were quite different, cyclization of each of 
the compounds led to the same cyclopentapeptide (see later). 
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The cyclization of 4c (1.5×10–3 M solution in DMF, containing 1% of DIEA) was 
performed with 2.3 equiv. of DEPC overnight. After prep. TLC, the cyclopentapeptide 5c was 
isolated in excellent yield (91%, Scheme 4, Table 2). The epimeric cyclopentapeptides (R)-5d 
and (S)-5d were prepared from the corresponding peptides (R)-4d and (S)-4d 3), respectively, 
via the TBTU/HOBt method. The product (R)-5d, containing (R)-Phe(2Me) and (S)-Phe, was 
obtained in slightly higher yield than (S)-5d with two S-configured amino acids in the 
backbone (64 and 55%, resp.). For comparison, (R)-5d was also prepared via cyclization of 
(R)-4d with DEPC/DIEA in almost the same yield (61%). Both cyclopentapeptides could be 
purified conveniently by column chromatography or prep. TLC. The advantage of the DEPC 
method was the easier detection of the product and side products by TLC; therefore, this 
method was used for all other cyclizations. In the case of pentapeptide 4e, the mixture of 
epimers as well as (R)-4e and (S)-4e were cyclized under the same conditions (DEPC) leading 
to 5e, (R)-5e, and (S)-5e, respectively, in 73, 78, and 46% yield (Table 2). Finally, the 
cyclization of the epimers (R)-4f and (S)-4f gave the corresponding cyclopentapeptides (R)-5f 
and (S)-5f in 47 and 10% yield, respectively. 
 
Scheme 4 
 
It is worth mentioning that in all three cases of a pair of epimeric pentapeptides 
containing Phe(2Me) and one or two S-configured amino acids (4d, 4e, and 4f), the 
cyclization of the (R)-Phe(2Me) epimer proceeded with higher efficiency. Furthermore, a 
dimeric cycodecapeptide was not detected in any of the cyclization experiments, in 
3)  Under the same conditions, the sparingly soluble (S)-4d’ and the fairly soluble (S)-4d” 
gave the same cyclopentapeptide (S)-5d in 56 and 55% yield, respectively. 
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accordance with the results reported in [17]: in all examples with a N-terminal Gly, only 
monomeric cyclopentapeptides were formed. The highest yields of cyclopentapeptide 5 (78–
91%) were obtained when Aib was the C-terminal amino acid. With regard to the helical 
conformations of derivatives of pentapeptides 4 (cf. [26]), with the N- and C-terminus remote 
from each other, the high efficiency of the cyclizations is remarkable. In the case of a C-
terminal Aib, the reason may be the smooth formation of a 1,3-oxazol-5(4H)-one in the 
activation step [22], in which the C-terminal intramolecular H-bond, which contributes 
significantly to the stability of the helix, is broken. 
 
2.2. Crystal Structures of Cyclopentapeptides. – Suitable crystals of cyclo(Gly-Aib-
(R,S)-Phe(2Me)-Aib-Gly) (5b) were obtained from MeOH/H2O. The space group is non-
centrosymmetric, but not polar; thus the crystals are racemic. The asymmetric unit contains 
two molecules, A and B, of the cyclopeptide plus one molecule of H2O.  Although the 
diagrams for A and B show opposite enantiomorphs (Fig. 1), the space group symmetry 
generates both enantiomorphs for each of molecule A and B.  The overall conformations of 
molecules A and B are very similar, with only small variations in the twists within the rings 
and slight differences in the orientations of the Ph groups.  The largest differences shown in 
the torsion angles are about the C(8)–C(9) (~12°), C(11)–C(12) (~21°), C(12)–N(13) (~23°), 
C(14)–C(15) (~ 8°), N(1)–C(15) (~17°), C(6)–C(19) (~16°) and C(19)–C(20) (~16°) bonds.  
The Ph ring in each molecule is disordered due to in plane waggling of the ring about the ipso 
C–C bond. Two sets of positions were defined for the atoms of each Ph ring.  
 
Fig. 1. ORTEP Plot [31] of the molecular structure of the two symmetry-independent 
molecules A (with (R)-Phe(2Me)) and B (with (S)-Phe(2Me)) of cyclopentapeptide 5b (50% 
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probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms and minor 
component of the disordered Ph ring in each molecule omitted for clarity) 
 
Each N-H group acts as a donor for H-bonding interactions (Table 3). All O-atoms, 
except O(14) of molecule A, are H-bond acceptors. In both molecules A and B, the NH group 
on the opposite side of the ring to the Ph substituent forms an intramolecular cross-ring H-
bond with the carbonyl O-atom immediately adjacent to the Ph substituent (N(13)–H···O(5) 
and N(43)-H···O(35)) to give graph set motifs [32] of S(10), i.e., forming a β-turn of type I 
and I’, respectively (Table 4). 
The type A molecules are H-bonded to each other via both Aib NH groups (N(4)–H 
and N(10)–H) donating to the Aib carbonyl O-atoms (O(2) and O(8), resp.) of different 
neighboring molecules which are related by different c-glides. Each of these interactions link 
the type A molecules into extended chains which run parallel to the [001] direction and can be 
described by a graph set motif of C(5). The combination of the two interactions also links the 
molecules end-to-end in the [010] direction. This results in two-dimensional layers of type A 
molecules which lie parallel to the (100) plane and in which R4,4(27) ring motifs involving 
each of N(4)–H and N(10)–H twice via four molecules are discernable. The same type of 
interactions link the type B molecules to each other, also forming layers parallel to the (100) 
plane.   
In addition, N(1)–H of molecule A forms an intermolecular H-bond with O(1) of a 
neighboring H2O molecule. The H-atoms of the H2O molecule, in turn, donate to carbonyl O-
atoms of two different type B molecules (O(1)–H(11)···O(41ii), O(1)–H(12)···O(44)). The 
corresponding NH group in molecule B, (N(31)–H), forms an intermolecular interaction with 
O(11) of molecule A. These four interactions serve to cross-link parallel layers of type A and 
B molecules to form an extended H-bonded bilayer. There are no interactions between these 
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bilayers, because the Ph groups and other hydrophobic parts of the molecules face each other 
across the space between the bilayers. 
 
Table 3.  Intra- and Intermolecular H-Bonds of 5b (atom numbering refers to Fig. 1) 
 
All of the peptide bonds of the two independent molecules 5b are trans-configured as 
shown by the torsion angles ω (Table 4) 4). The R epimer of the previously synthesized 
cyclo(Gly-(R,S)-Phe(2Me)-Aib-Aib-Gly) [14c] shows the identical backbone conformation as 
molecule B of 5b (Table 4), and an almost perfect superimposition of the two structures is 
observed. This is not surprising taking into account that the conformation of cyclopeptides is 
mainly determined by the sequence of the amino acids: in both cases, two unsubstituted α-
amino acids (Gly) are followed by three α,α-disubstituted α-amino acids (Phe(2Me) and two 
Aib). On the other hand, it is astonishing that in the case of 5b the epimer with (S)-Phe(2Me) 
forms a β-turn type I’, whereas in 5a the same turn is formed by the (R)-Phe(2Me) epimer. 
 
Table 4. Selected Torsion Angles (°) φ, ψ, and ω of the Backbone of the 
Cyclopentapeptides 5a [14c] and 5b in the Crystal 
 
Suitable crystals of the pure (R)-Phe(2Me) epimer of cyclopentapeptide (R)-5f were 
obtained by crystallization from AcOEt/MeOH/hexane. The structure of C30H37N5O5·MeOH 
4)  Cyclopentapeptides are the smallest cyclopeptides with an all-trans configuration, shown 
in a series of crystal structures (e.g. [33]). A theoretical study of the minimum energy 
conformations resulted in 23 conformations including in most cases a β-turn and in a few 
cases one or two γ-turns [34]. 
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has two molecules of the peptide in the asymmetric unit (Fig. 2), as well as sites for 
disordered MeOH and/or H2O molecules. The solvent molecules could not be identified and 
modelled sufficiently well, so their contribution to the diffraction data was removed by using 
the SQUEEZE procedure (see exper. part). One of the peptide molecules has disorder of two 
atoms in the 5-membered ring and also shows evidence for slight conformational disorder of 
the peptide chain from C(45) to C(48), as well in the Ph rings. 
 The crystals are enantiomerically pure, however the absolute configuration of the 
molecule has not been determined. The enantiomer used in the refinement was based on the 
known S configuration at C(6) (Pro) and C(15) (Phe). The configuration at C(9) (Phe(2Me)) is 
therefore R. Both of the independent peptide molecules have the same configuration, but they 
differ quite significantly in the conformation of the peptide ring in the region between N(1) 
and C(6). The orientations of the Ph groups also differ between the two molecules.  
 
Fig. 2. ORTEP Plot [31] of the molecular structure of the two symmetry-independent 
molecules A and B of cyclopentapeptide (R)-5f (50% probability ellipsoids, arbitrary 
numbering of atoms, H-atoms bonded to C-atoms and one component of the disordered five-
membered ring in molecule B omitted for clarity) 
 
In molecule A, N(1)–H and N(4)–H form intramolecular H-bonds with amide O-atoms 
(graph sets S(8) and S(7), resp. [32]) (Table 3).  N(10)–H and N(13)–H form intermolecular 
H-bonds to amide O-atoms, the former being with molecule B (graph set D) and the latter 
with another molecule A to form extended zig-zag A···A···A chains which run parallel to the 
[100] direction (graph set C(8)). In molecule B, only N(44)–H makes an intramolecular H-
bond (graph set S(10)), forming a β-turn (Table 5). N(53)–H interacts with an amide O-atom 
of molecule A (graph set D). Other NH donors presumably are H-bonding to solvent O-atoms. 
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Considering only the above intermolecular interactions, the resulting network is composed of 
zig-zag chains of A molecules with pendant B molecules decorating the sides of the chain. 
 
Table 5. Selected Torsion Angles (°) φ, ψ, and ω of the Backbone of the 
Cyclopentapeptide (R)-5f in the Crystal  
 
As in the cases of 5a and 5b, all amide bonds in both conformations of (R)-5f are trans 
configured. Whereas the Gly-Phe(2Me) part of the two molecules is similar, significant 
differences are observed in the Pro-Aib-Phe part. In conformer A, the C=O group of Gly is 
involved in an intramolecular H-bond with NH of Phe forming an α-turn, and the C=O group 
of Phe(2Me) forms an H-bond with NH of Aib (γ-turn). This conformation is quite unusual. 
On the other hand, in conformer B, a β-turn with an H-bond between NH of Aib and C=O of 
Gly stabilizes the conformation. 
 
2.3. Conformations of Cyclopentapeptides 5 in Solution. As a representative example, 
cyclo(Gly-(R)-Phe(2Me)-Pro-Aib-Phe) ((R)-5f) was used for NMR studies in CDCl3. The 
assignment of the 1H-NMR signals was achieved by using COSY, TOCSY, HSQC, and 
HMBC techniques. The NH signals of Gly (6.85–6.0 ppm) and Phe (7.63 ppm) could be 
assigned on the basis of the TOCSY spectrum, and the HMBC spectrum allowed the 
identification of the NH signals of the α,α-disubstituted α-amino acids Phe(2Me) (6.30 ppm) 
and Aib (7.08 ppm). As solvent and temperature dependence of the chemical shift of amide 
NH signals can be used as an indication of intra- and intermolecular H-bonds [22e][35], the 
1H-NMR spectrum was measured in CDCl3 containing 1–10% of (D6)DMSO (Fig. 3). 
Whereas the chemical shift of the NH signal of Phe(2Me) is strongly solvent dependent, the 
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NH signals of Phe, Aib and Gly are barely influenced 5), i.e., these NH groups are not easily 
accessible for solvent molecules. 
 
Fig. 3. Dependence of the chemical shifts of the NH resonances of (R)-5f as a function 
of the (D6)DMSO concentration (% v/v) in CDCl3 
 
A NOESY spectrum of (R)-5f in CDCl3 showed cross peaks for the interactions 
depicted in Fig. 4a. Under the assumption that all peptide bonds adopt the trans 
conformation, this result does neither correlate with conformation A nor conformation B in 
the crystal (Fig. 2). Examination of a Dreiding model of a conformation of (R)-5f fulfilling 
the special conditions resulting from the NOESY spectra and taking into consideration that 
NH of Phe(2Me) is not involved in an intramolecular H-bond, the presence of a γ-turn formed 
between NH(Aib) and CO(Phe(2Me)) as in conformation A in the crystal is likely. 
Furthermore, a second γ-turn formed by a H-bond between NH(Gly) and CO(Aib) seems 
plausible, explaining the solvent independence of NH(Gly). The fact that also the chemical 
shift of NH(Phe) is not solvent dependent may be explained by steric shielding by the Ph 
group of Phe. Therefore, the conformation depicted in Fig. 4b with two γ-turns is proposed for 
the molecule in solution. 
 
Fig. 4. a) Observed NOE Signals of (R)-5f in CDCl3; b) Proposed all-trans 
Conformation of (R)-5f in CDCl3 Solution 
5)  The NH signal of Aib (7.08 ppm, CDCl3) could not be detected after addition of 2–10% 
(D6)DMSO because it then overlaps with the m of the aromatic H-atoms (7.2–7.1 ppm). 
As the width of the aromatic m is only 0.2 ppm, it can be concluded that the chemical 
shift of NH(Aib) is rather constant and not solvent dependent. 
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3. Conclusions. – The present study shows that Aib- and Phe(2Me)-containing 
pentapeptides undergo smooth cyclization reactions to give the corresponding 
cyclopentapeptides. These 15-membered rings are generally formed in high yields. It is 
important to emphasize that dimerization was not observed in any of the studied cases (cf. 
[2][14c][16–18]). The best results were obtained by using DEPC/DIEA in DMF or 
TBTU/HOBt/DIEA in DMF as the coupling reagent at room temperature. The highest yields 
were achieved in the cases of pentapeptides with a N-terminal Gly and a C-terminal Aib unit, 
leading to the cyclopentapeptides in 73–91% yield, whereas the yields of analogous 
pentapeptides with a C-terminal Gly or Phe were in the range of 45–64%. Exceptions are the 
two pentapeptides H-Gly-(S)-Phe(2Me)-Pro-Aib-Aib-OH ((S)-4e) and H-Gly-(S)-Phe(2Me)-
Pro-Aib-Phe-OH ((S)-4f), which gave the cyclopentapeptides in only 46 and 10% yield, 
respectively. The high efficiency of the cyclization in the case of C-terminal Aib peptides may 
be explained by the easy formation of 4,4-dimethyl-1,3-oxazol-5(4H)-ones [22] as a result of 
the ‘gem-dimethyl effect’ (Thorpe-Ingold effect) (see, e.g., [36]). Furthermore, the significant 
difference in the yields of the cyclization of pentapeptides 4e and 4f containing the (R)-
Phe(2Me)-Pro or (S)-Phe(2Me)-Pro dipeptide unit has to be mentioned (see Table 2). In both 
cases, the ring closure of the (R)-Phe(2Me)-Pro epimer was much more efficient than that of 
the (S)-Phe(2Me)-Pro epimer, in agreement with the known result that the formation of cyclic 
peptides containing a D-amino acid is easier than that of the all-L peptide (see introduction, 
e.g., [12][13]). 
The crystal structures of the two selected cyclopentapeptides cyclo(Gly-Aib-(R,S)-
Phe(2Me)-Aib-Gly) (5b) and cyclo(Gly-(R)-Phe(2Me)-Pro-Aib-Phe) ((R)-5f) are quite 
different. Whereas the racemic 5b forms a β-turn of type I and I’, respectively, the 
enantiomerically pure (R)-5f exists in two different conformations. In one of them, again a β-
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turn is formed with torsion angles between those of types I and III. In the second 
conformation, an inverse γ-turn and, surprisingly, an α-turn stabilize the structure of the 
molecule. Based on NMR studies of (R)-5f in CDCl3, a conformation with two γ-turns is most 
likely in solution. 
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Experimental part 
 
1. Abbreviations. Aib, 2-aminoisobutyric acid (2-methylalanin); DEPC, diethyl 
phosphorocyanidate; DIEA, ethyl(diisopropyl)amine (Hünig base); DPPA, diphenyl 
phosphorazidate; HOBt, 1-hydroxybenzotriazole; TBTU, O-(1H-benzotriazol-1-yl)-
N,N,N',N'-tetramethyluronium tetrafluoroborate; Z, benzyloxycarbonyl. 
2. General. See [25][26][37]. The synthesis of all used protected pentapeptides 6 has 
been described in [26]. Solvents were purified by standard procedures. TLC: Merck TLC 
glass plates, silica gel 60 F254. Preparative layer chromatography (PLC): Merck glass plates, 
silica gel 60 F254. Column chromatography (CC): Uetikon-Chemie, silica gel C-560 (0.04-
0.063 mm) or Merck 60, 0.040–0.063 mm. High-performance liquid chromatography 
(HPLC): Varian-2510 and UV detector Varian-2550, Spherisorb ODS2, 5 µm, 250×4.6 mm 
(analytical) and Spherisorb ODS2, 5 µm, 250×20 mm (prep.). M.p. were measured on a 
Mettler-FP-5 apparatus, uncorrected. [α]D-Values were determined on a Perkin-Elmer-241 
polarimeter at 21°. IR Spectra were recorded on a Perkin-Elmer-781 spectrometer, in KBr. 
1H- and 13C-NMR spectra were recorded on a Bruker AC-300, Bruker ARX-300 or Bruker 
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AMX-600 spectrometer at 300 or 600 (1H) and 75.5 or 150 MHz (13C), respectively, in CDCl3, 
CD3OD or (D6)DMSO. The multiplicity of 13C signals was determined by the DEPT 
technique. ESI- and APCI-MS were measured on a Finnigan TSQ-700 instrument; m/z (rel. 
%).  
General Procedure 1 (GP 1, Saponification of Peptide Methylesters). To a soln. of a 
peptide methyl ester (1 mmol) in 10 ml of THF/MeOH/H2O (3:1:1) at 0° was added 
LiOH.H2O (2.5 mmol). The mixture was stirred at 0° for 1 h. Then, it was neutralized by 
addition of aq. 2N HCl and the org. solvents were evaporated (rotavapor). The residue was 
dissolved in AcOEt und the mixture washed with aq. 0.5N HCl. The org. phase was dried 
(Na2SO4) and the solvent evaporated. 
General Procedure 2 (GP 2, Hydrogenolysis). A mixture of Z-protected peptide in 
MeOH and ca. 10% Pd/C (10%) at r.t. was stirred under H2 (balloon) over night. The mixture 
was filtered through a Celite pad and the solvent of the filtrate evaporated to dryness. 
General Procedure 3 (GP 3, Transfer Hydrogenolysis). To a mixture of Z-protected 
peptide (1 mmol) and the same amount of Pd/C (10%) in MeOH was added HCO2NH4 (5 
mmol). The mixture was heated at reflux for 10 min, the hot mixture filtered through a Celite 
pad and washed with MeOH. The solvent of the filtrate was evaporated to dryness. 
General Procedure 4 (GP 4, Hydrolysis of Peptide Amides). A soln. of Z-protected 
peptide amide (1 mmol) in 3N HCl (THF/H2O 1:1) was stirred at r.t. for 1–4.5 h. Then, 2N 
HCl was added and the mixture extracted with Et2O. The org. phase was dried (Na2SO4), and 
the solvent was evaporated. 
General Procedure 5 (GP 5, Cyclization with DEPC). To a ca. 1.5×10–3 M soln. of a 
deprotected pentapeptide (0.1 mmol) in DMF (67 ml) at 0° was added drop-wise DEPC (0.2–
0.4 mmol) and DIEA (1% v/v), and the mixture was stirred over night at r.t. Then, DMF was 
evaporated and the residue purified chromatographically and crystallized. 
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3. Synthesis of the Deprotected Pentapeptides 4. 3.1. H-Gly-Aib-(R,S)-Phe(2Me)-Aib-
Gly-OH (4a). 3.1.1. Z-Gly-Aib-(R,S)-Phe(2Me)-Aib-Gly-OH (7a). To a soln. of Z-Gly-Aib-
(R,S)-Phe(2Me)-Aib-Gly-OMe (6a, 1.46 g, 2.39 mmol) in MeOH (1 ml) at r.t. was added 
slowly 2N NaOH (8 ml) and the mixture stirred for 20 min. Then, 2N HCl was added until pH 
1, and the mixture was extracted with CH2Cl2. The combined org. phase was dried (Na2SO4), 
the solvent was evaporated, and the crystalline product was dried: 1.22 g (85%) of 7a. 
Colorless crystals. M.p. 95.4–96.9°. IR (KBr): 3310s, 3060m, 3030m, 2980m, 2940m, 1665s, 
1590s, 1455m, 1385m, 1260m, 1240m, 1220m, 1190m, 700m. 1H-NMR (CD3OD): 8.21 (s, 
NH); 7.86 (t-like, NH); 7.77, 7.46 (2s, 2 NH); 7.3–7.2 (m, 8 arom. H); 7.15–7.1 (m, 2 arom. 
H); 5.04 (s, PhCH2O); 4.1–3.6 (m, 2 CH2(Gly)); 3.39, 3.02 (AB, JAB = 13.6, PhCH2); 1.49, 
1.48, 1.45, 1.39, 1.34 (5s, 2 Me2C, Me(Phe(2Me)). 13C-NMR (CD3OD): 178.1, 177.0, 176.1, 
172.9, 172.0 (5s, 4 CO(amide), COOH); 159.3 (s, CO(urethane)); 138.0, 137.8 (2s, 2 arom. 
C); 132.1, 129.5, 129.1, 128.8, 127.9 (5d, 10 arom. CH); 67.8 (t, PhCH2O); 61.2, 58.4, 58.0 
(3s, 2 C(2)(Aib), C(2)(Phe(2Me))); 45.1, 41.9, 41.5  (3t, 2 CH2(Gly), PhCH2); 26.6, 26.3, 
25.1, 24.7, 24.0 (5q, 2 Me2C, Me(Ph(2Me))). ESI-MS(neg.): 596 ([M–1]–). Anal. calc. for 
C30H39N5O8.0.5 H2O (606.68): C 59.39, H 6.65, N 11.45; found: C 59.25, H 6.40, N 11.56. 
3.1.2. H-Gly-Aib-(R,S)-Phe(2Me)-Aib-Gly-OH (4b). According to GP 2, a mixture of 
7a (330 mg, 0.552 mmol) and Pd/C (33 mg) in MeOH (4 ml) was hydrogenated for 19 h: 220 
mg (86%) of 4b. Colorless solid. M.p. 138.9–140.7°. IR (KBr): 3380m, 3060m, 3020m, 
2980m, 2940m, 1710s (br), 1535s, 1385m, 705w. 1H-NMR (D2O): 7.4–7.3 (m, 3 arom. H); 
7.25–7.2 (m, 2 arom. H); 3.85–3.75 (m, 2 CH2(Gly)); 3.32, 3.10 (AB, JAB =13.6, PhCH2); 
1.55, 1.52, 1.48, 1.44, 1.43 (5s, 2 Me2C, Me(Phe(2Me))). 13C-NMR (D2O): 179.7, 179.4, 
178.6, 178.1, 169.4 (5s, 4 CO (amide), COOH); 138.5 (s, 1 arom. C); 133.7, 131.2, 130.1 (3d, 
5 arom. CH); 62.9, 59.9 (2s, 2 C(2)(Aib), C(2)(Phe(2Me))); 46.3, 43.3, 43.2 (3t, 2 CH2(Gly), 
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PhCH2); 27.2, 27.0, 26.6, 25.3 (4q, 2:1:1:1, 2 Me2C, Me(Phe(2Me))). ESI-MS: 502 (8, 
[M+K]+), 486 (29, [M+Na]+), 464 (100, [M+1]+). 
3.2. H-Gly-(R,S)-Phe(2Me)-Gly-Aib-Aib-OH (4c). 3.2.1. Z-Gly-(R,S)-Phe(2Me)-Gly-
Aib-Aib-OH (7c). According to GP 4, Z-Gly-(R,S)-Phe(2Me)-Gly-Aib-Aib-N(Me)Ph (6c, 425 
mg, 0.619 mmol) was hydrolyzed. After 4.5 h, the mixture was extracted with AcOEt and the 
solvent evaporated: 364 mg (98%) of 7c. Colorless solid. M.p. 122.7–124.2°. IR (KBr): 
3310s, 3060m, 3030m, 2980m, 2940m, 1710s, 1660s, 1530s, 1470m, 1455m, 1385m, 1365m, 
1280m, 1260m, 1230m, 1150m, 700m. 1H-NMR (CDCl3 + 2 drops of CD3OD): 7.34, 7.68 (2s, 
2 NH); 7.35–7.3 (m, 8 arom. H, 2 NH); 7.1–7.05 (m, 2 arom. H); 6.95 (s, NH); 5.08 (s, 
PhCH2O); 3.8–3.75 (m, 2 CH2(Gly)); 3.34, 3.05 (AB, JAB = 13.6, PhCH2); 1.52, 1.45, 1.42, 
1.38 (4s, 2:1:1:1, 2 Me2C, Me(Phe(2Me))). 13C-NMR (CDCl3 + 2 drops of CD3OD): 176.6, 
175.6, 175.1, 170.92, 170.88 (5s, 4 CO(amide), COOH); 157.4 (s, CO(urethane)); 136.0, 
135.6 (2s, 2 arom. C); 130.5, 128.4, 128.2, 127.8, 126.9 (5d, 10 arom. CH); 67.1 (t, PhCH2O); 
59.5, 56.8, 56.4 (3s, 2 C(2)(Aib), C(2)(Phe(2Me))); 44.8, 44.4, 40.6 (3t, 2 CH2(Gly), PhCH2); 
25.2, 24.8, 24.5, 24.4, 22.7 (5q, 2 Me2C, Me(Phe(2Me))). ESI-MS: 602 (100, [M+Na]+), 598 
(5, [M+1]+).   
3.2.2. H-Gly-(R,S)-Phe(2Me)-Gly-Aib-Aib-OH (4c). According to GP 2, 7c (48 mg, 
0.08 mmol) in MeOH (2 ml) was treated with H2 in the presence of Pd/C (5 mg). After 30 
min, the product precipitated. After addition of DMF (40 ml), the mixture was filtered 
through a Celite pad and the solvent evaporated: 35 mg (94%) of 4c.  
Alternatively, transfer hydrogenolysis (GP 3) of 7c (543 mg (0.91 mmol) in MeOH 
(20 ml) with HCO2NH4 (290 mg, 4.6 mmol) and Pd/C (544 mg) gave 390 mg (93%) of 4c. 
Colorless solid. M.p. 172.7–173.2°. IR (KBr): 3400m, 3280s, 3060m, 3030m, 2980m, 2940m, 
1680s, 1660s, 1640s, 1565s, 1535s, 1470m, 1455m, 1440m, 1425m, 1405m, 1390m, 1365m, 
1330m, 1280m, 710m. 1H-NMR (D2O): 7.4–7.35 (m, 3 arom. H, 2 NH); 7.2–7.15 (m, 2 arom. 
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H); 3.9–3.75 (m, 2 CH2(Gly)); 3.31, 3.12 (AB, JAB = 13.3, PhCH2); 1.51, 1.44 (2s, 2:3, 2 
Me2C, Me(Phe(2Me))). 13C-NMR (D2O): 184.6, 178.7, 177.7, 173.1, 169.5 (5s, 4 CO(amide), 
COOH); 138.1 (s, 1 arom. C); 133.2, 131.2 130.1 (3d, 5 arom. CH); 63.2, 60.8, 59.8 (3s, 2 
C(2)(Aib), C(2)(Phe(2Me))); 45.9, 43.6, 43.4 (3t, 2 CH2(Gly), PhCH2); 27.1, 26.9, 26.8, 24.7 
(4q, 2:1:1:1, 2 Me2C, Me(Phe(2Me))). ESI-MS: 486 (28, [M+Na]+), 464 (100, [M+1]+). 
3.3. H-Gly-(R,S)-Phe(2Me)-Gly-Aib-Phe-OH (4d). According to GP 2, Z-Gly-(R,S)-
Phe(2Me)-Gly-Aib-Phe-OBn (6d, 127 mg, 0.169 mmol) was deprotected: 88 mg (99%) 4d 
(mixture of diastereoisomers). Colorless foam. M.p. 146.8–150.0°. IR (KBr): 3320m, 3060m, 
3030m, 2930m, 1660s, 1535m, 1500m, 1200m, 1135m, 700m. 1H-NMR (CD3OD): 7.35–7.1 
(m, 10 arom. H); 4.5–4.45 (m, CH(2)(Phe)); 3.95–3.55 (m, 2 CH2(Gly)); 3.45–3.35, 3.25–3.0 
(2m, 1:3, 2 PhCH2); 1.48, 1.43, 1.39, 1.35 (4s, Me2C, Me(Phe(2Me))). 13C-NMR (CD3OD): 
176.8, 176.6, 176.3, 171.1, 167.9, 167.8 (6s, 4 CO(amide), COOH); 139.1, 138.9, 137.4, 
137.3 (4s, 2 arom. C); 131.8, 131.7, 130.7, 129.5, 129.3, 129.2, 128.9, 128.1, 127.9, 127.6, 
126.8 (11d, 10 arom. CH); 61.5, 61.4, 58.3, 58.2 (4s, C(2)(Aib), C(2)(Phe(2Me))); 54.1 (d, 
CH(2)(Phe)); 44.7, 41.9, 41.0, 38.8, 38.6 (5t, 2 CH2(Gly), 2 PhCH2); 25.8, 25.7, 25.5, 23.8, 
23.3 (5q, Me2C, Me(Phe(2Me))). ESI-MS: 548 (100, [M+Na]+], 526 (88, [M+1]+), 361 (23, 
[M–Phe]+).  
3.4. H-Gly-(R)-Phe(2Me)-Gly-Aib-Phe-OH ((R)-4d). 3.4.1. Z-Gly-(R)-Phe(2Me)-Gly-
Aib-Phe-OH ((R)-7d). According to GP 1, Z-Gly-(R)-Phe(2Me)-Gly-Aib-Phe-OMe ((R)-6d’, 
505 mg, 0.750 mmol) in THF/MeOH/H2O (3:1:1, 6 ml) was treated with LiOH.H2O (81 mg, 
1.930 mmol): 464 mg (94%) (R)-7d. Colorless solid. M.p. 146.8–148.0°. [α]D21 = +74.6 (c = 
1.02, EtOH). IR (KBr): 3300m, 3060m, 3030m, 2980m, 2930m, 1725s, 1670s, 1535s, 1455m, 
1385m, 1335m, 1265m, 1225m, 1190m, 1170m, 1150m, 700m. 1H-NMR (CDCl3 + 2 drops of 
CD3OD): 7.78 (br. s, NH); 7.72 (s, NH); 7.40 (d, J = 7.4, NH); 7.35–7.0 (m, 15 arom. H, 1 
NH); 5.06, 5.04 (AB, JAB = 12.3, PhCH2O); 4.6–4.5 (m, CH(2)(Phe)); 3.8–3.55 (m, 2 
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CH2(Gly)); 3.4–3.2, 3.1–3.0 (2m, 1:1, 2 PhCH2); 1.44, 1.37, 1.31 (3s, Me2C; Me(Phe(2Me))). 
13C-NMR (CD3OD): 177.1, 176.8, 174.6, 172.5, 171.5 (5s, 4 CO(amide), COOH); 159.4 (s, 
CO(urethane)); 138.5, 138.0, 137.5 (3s, 3 arom. C); 131.8, 130.5, 129.5, 129.4, 129.3, 129.1, 
128.9, 127.9, 127.7 (9d, 15 arom. CH); 68.0 (t, PhCH2O); 61.0, 58.2 (2s, C(2)(Aib), 
C(2)(Phe(2Me))); 55.2 (d, CH(2)(Phe)); 45.2, 44.8 (2t, 2 CH2(Gly)); 41.6, 38.4 (2t, 2 PhCH2); 
25.8, 25.5, 23.6 (3q, Me2C, Me(Phe(2Me))). ESI-MS: 682 (100, [M+Na]+). Anal. calc. for 
C35H41N5O8 (659.74): C 63.72, H 6.26, N 10.62; found: C 63.42, H 6.44, N 10.61. 
3.4.2. H-Gly-(R)-Phe(2Me)-Gly-Aib-Phe-OH ((R)-4d). According to GP 2, (R)-7d 
(358 mg, 0.681 mmol) in MeOH (6 ml) was deprotected (6 h): 285 mg (quant.) of (R)-4d. 
Colorless solid. M.p. 169.0–171.8°. [α]D21 = +67.4 (c = 0.522, trifluoroethanol). IR (KBr): 
3280s, 3060m, 3030m, 2980m, 2930m, 1675s, 1535s, 1455m, 1440m, 1385m, 1330m, 1280m, 
1245m, 1180m, 1155m, 700m. 1H-NMR (CDCl3 + 2 drops of TFA): 7.4–7.1 (m, 10 arom. H); 
4.7–4.6 (m, CH(2)(Phe)); 3.9–3.6 (m, 2 CH2(Gly)); 3.45–3.05 (m, 2 PhCH2); 1.47, 1.42, 1.39 
(3s, Me2C; Me(Phe(2Me))). 13C-NMR (CD3OD + 2 drops of TFA): 177.0, 176.6, 174.8, 
171.3, 167.7 (5s, 4 CO(amide), COOH); 138.5, 137.4 (2s, 2 arom. C); 131.8, 130.4, 129.4, 
129.3, 128.1, 127.8 (6d, 10 arom. CH); 61.4, 58.2 (2s, C(2)(Aib), C(2)(Phe(2Me))); 55.3 (d, 
CH(2)(Phe)); 44.8, 41.9, 41.4, 38.3 (4t, 2 CH2(Gly), 2 PhCH2); 25.6, 23.6 (2q, 2:1, Me2C, 
Me(Phe(2Me))). APCI-MS: 526 ([M+Na]+).  
3.5. H-Gly-(S)-Phe(2Me)-Gly-Aib-Phe-OH ((S)-4d). 3.5.1. Z-Gly-(S)-Phe(2Me)-Gly-
Aib-Phe-OH ((S)-7d). According to GP 1, Z-Gly-(S)-Phe(2Me)-Gly-Aib-Phe-OMe ((S)-6d’, 
461 mg, 0.684 mmol) in THF/MeOH/H2O (3:1:1, 6 ml) was treated with LiOH.H2O (72 mg, 
1.716 mmol): 439 mg (97%) (S)-7d. Colorless solid. M.p. 163.0–165.4°. [α]D21 = –67.2 (c = 
0.93, EtOH). IR (KBr): 3290m, 3060w, 3030w, 2980m, 2930m, 1730s, 1660s, 1650s, 1535s, 
1465m, 1410m, 1385m, 1365m, 1330m, 1260m, 1230m, 1195m, 1170m, 700m. 1H-NMR 
(CD3OD): 8.16 (t-like, NH); 8.10 (s, NH); 7.77 (s, NH); 7.54 (d, J = 7.8, NH); 7.4–7.1 (m, 15 
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arom. H); 5.10, 5.03 (AB, JAB = 12.4, PhCH2O); 4.65–4.55 (m, CH(2)(Phe)); 3.85–3.5 (m, 2 
CH2(Gly)); 3.41 (A of AB, JAB = 13.5, 1 H of PhCH2); 3.2–3.05 (m, 3 H of 2 PhCH2); 1.46, 
1.41, 1.33 (3s, Me2C; Me(Phe(2Me))). 13C-NMR (CD3OD): 177.3, 177.0, 174.7, 172.5, 171.5 
(5s, 4 CO(amide), COOH); 159.4 (s, CO(urethane)); 138.6, 138.1, 137.6 (3s, 3 arom. C); 
131.9, 130.5, 129.5, 129.4, 129.2, 129.1, 128.9, 127.9, 127.7 (9d, 15 arom. CH); 68.0 (t, 
PhCH2O); 61.0, 58.3 (2s, C(2)(Aib), C(2)(Phe(2Me))); 55.6 (d, CH(2)(Phe)); 45.2, 44.9 (2t, 2 
CH2(Gly)); 41.2, 38.4 (2t, 2 PhCH2); 26.2, 25.1, 23.6 (3q, Me2C, Me(Phe(2Me))). ESI-MS: 
682 (100, [M+Na]+). Anal. calc. for C35H41N5O8 (659.74): C 63.72, H 6.26, N 10.62; found: C 
63.83, H 6.35, N 10.31. 
3.5.2. H-Gly-(S)-Phe(2Me)-Gly-Aib-Phe-OH ((S)-4d). According to GP 2, (S)-7d (317 
mg, 0.481 mmol) in MeOH (15 ml) was deprotected (4.5 h). During the evaporation of 
MeOH, 121 mg of sparingly soluble (S)-4d’ precipitated. Evaporation of the mother liquor 
gave 124 mg well soluble (S)-4d”. Total yield of (S)-4d: 245 mg (97%). Data of (S)-4d’: 
Colorless solid. M.p. 132.5–134.1°. [α]D21 = +74.9 (c = 0.513, trifluoroethanol). IR (KBr): 
3370m, 3340m, 3240s, 3015m, 2980m, 2930m, 1650s, 1570s, 1530s, 1455m, 1400m, 1385m, 
1365m, 1260m, 1240m, 700m. 1H-NMR (CD3OD + 2 drops of TFA): 7.35–7.1 (m, 10 arom. 
H); 4.65–4.55 (m, CH(2)(Phe)); 3.85–3.55 (m, 2 CH2(Gly)); 3.38 (A of AB, JAB = 13.5, 1 H of  
PhCH2); 3.25–3.05 (m, 3 H of 2 PhCH2); 1.50, 1.47, 1.39 (3s, Me2C; Me(Phe(2Me))). 13C-
NMR (CD3OD + 2 drops of TFA): 177.0, 176.6, 174.9, 171.2, 167.7 (5s, 4 CO(amide), 
COOH); 138.6, 137.4 (2s, 2 arom. C); 131.8, 130.5, 129.4, 129.3, 128.1, 127.8 (6d, 10 arom. 
CH); 61.4, 58.3 (2s, C(2)(Aib), C(2)(Phe(2Me))); 55.6 (d, CH(2)(Phe)); 44.8, 41.9, 41.5, 38.3 
(4t, 2 CH2(Gly), 2 PhCH2); 26.2, 24.9, 23.4 (3q, Me2C, Me(Phe(2Me))). ESI-MS: 564 (10, 
[M+K]+), 548 (21, [M+Na]+), 526 (100, [M+1]+).  
Data of (S)-4d”: Colorless solid. M.p. 156.4–158.8°. [α]D21 = –17.7 (c = 0.494, 
trifluoroethanol). IR (KBr): 3400s, 3300s, 3060m, 3030m, 2980m, 2930m, 1660s, 1600s, 
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1570s, 1455m, 1395m, 1330m, 1280m, 1240m, 1215m, 1200m, 1155m, 745m, 700m. 1H-NMR 
(CD3OD): 7.35–7.1 (m, 10 arom. H); 4.45–4.35 (m, CH(2)(Phe)); 3.85–3.4 (m, 2 CH2(Gly)); 
3.3–3.05 (m, 2 PhCH2); 1.46, 1.38 (2s, 1:2, Me2C; Me(Phe(2Me))). 13C-NMR (CD3OD): 
178.2, 176.2, 176.1, 171.2, 168.7 (5s, 4 CO(amide), COOH); 139.6, 137.2 (2s, 2 arom. C); 
131.8, 130.8, 129.3, 129.1, 128.1, 127.4 (6d, 10 arom. CH); 61.4, 58.2 (2s, C(2)(Aib), 
C(2)(Phe(2Me))); 57.6 (d, CH(2)(Phe)); 44.5, 42.8, 42.4, 38.8 (4t, 2 CH2(Gly), 2 PhCH2); 
26.6, 24.7, 23.2 (3q, Me2C, Me(Phe(2Me))). ESI-MS: 548 (30, [M+Na]+), 526 (100, [M+1]+).  
3.6. H-Gly-(R,S)-Phe(2Me)-Pro-Aib-Aib-OH (4e). 3.6.1. Z-Gly-(R,S)-Phe(2Me)-Pro-
Aib-Aib-OH (7e). According to GP 4, Z-Gly-(R,S)-Phe(2Me)-Pro-Aib-Aib-N(Me)Ph (6e, 538 
mg, 0.740 mmol) was hydrolyzed (1 h). Filtration of the precipitate gave 273 g of 7e. After 
evaporation of the solvent and crystallization from CH2Cl2/Et2O/hexane additional 109 mg of 
7e were obtained. Total yield: 382 mg (81%). 
3.6.2. H-Gly-(R,S)-Phe(2Me)-Pro-Aib-Aib-OH (4e). Hydrogenolysis of 7e (190 mg, 
0.298 mmol) in MeOH (3 ml) with HCO2NH4 (95 mg) and Pd/C (190 mg) according to GP 3 
gave 143 mg (96%) of 4e. 
3.7. H-Gly-(R)-Phe(2Me)-Pro-Aib-Aib-OH ((R)-4e). 3.7.1. Z-Gly-(R)-Phe(2Me)-Pro-
Aib-Aib-OH ((R)-7e). According to GP 4, Z-Gly-(R)-Phe(2Me)-Pro-Aib-Aib-N(Me)Ph ((R)-
6e, 298 mg, 0.410 mmol) was hydrolyzed (1 h): 215 mg (82%) of (R)-7e. Colorless solid. 
M.p. 125.0–125.7°. [α]D21 = +119.0 (c = 0.742, EtOH). IR (KBr): 3420m, 3340s, 3290s, 
3060m, 3030m, 2990m, 2949m, 1720s, 1675s, 1605s, 1540s, 1465m, 1420m, 1390m, 1365m, 
1310m, 1285m, 1240s, 1160m, 1050m, 765m, 700m. 1H-NMR (CD3OD): 8.17, 7.76, 7.55 (3s, 
3 NH); 7.4–7.15 (m, 8 arom. H); 7.15–7.1 (m, 2 arom. H); 5.11, 5.08 (AB, JAB = 12.4, 
PhCH2O); 4.26 (t, J = 8.3, CH(2)(Pro)); 3.92, 3.71 (AB, JAB = 17.2, CH2(Gly)); 3.85–3.7, 
3.65–3.5 (2m, CH2(5)(Pro)); 3.54, 3.06 (AB, JAB = 13.6, PhCH2);  2.35–2.2, 2.05–1.95, 1.95–
1.8, 1.8–1.6 (4m, 1 H each, CH2(3), CH2(4)(Pro)); 1.52, 1.51, 1.47, 1.46, 1.31 (5s, 2 Me2C, 
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Me(Phe(2Me))). 13C-NMR (CD3OD): 178.1, 176.7, 175.2, 174.4, 171.4 (5s, 4 CO(amide), 
COOH); 159.3 (s, CO(urethane)); 138.1 (s, 2 arom. C); 132.3, 129.5, 129.2, 128.9, 127.7 (5d, 
10 arom. CH); 67.8 (t, PhCH2O); 65.3 (d, CH(2)(Pro)); 60.0, 58.1, 57.1 (3s, 2 C(2)(Aib), 
C(2)(Phe(2Me))); 50.0 (t, CH2(5)(Pro)); 44.1 (t, CH2(Gly)); 41.9 (t, PhCH2); 29.8 (t, 
CH2(3)(Pro)); 27.0 (t, CH2(4)(Pro)); 27.5, 26.2, 24.4, 24.1, 21.0 (5q, 2 Me2C, Me(Phe(2Me))). 
ESI-MS: 660 (100, [M+Na]+).  
3.7.2. H-Gly-(R)-Phe(2Me)-Pro-Aib-Aib-OH ((R)-4e). According to GP 3, (R)-7e (280 
mg, 0.550 mmol) in MeOH (8 ml) was treated with HCO2NH4 (139 mg, 2.20 mmol) and Pd/C 
(281 mg): 209 mg (95%) of (R)-4e). Colorless solid. M.p. 187.3–190.4°. [α]D21 = +71.8 (c = 
0.301, H2O). IR (KBr): 3350s, 3260s, 3060m, 3030m, 2980m, 2940m, 2870m, 1730s, 1650s, 
1565s, 1535s, 1455m, 1400s, 1360m, 1280m, 1240m, 1210m, 1180m, 1160m, 705m. 1H-NMR 
(CD3OD): 7.4–7.2 (m, 3 arom. H); 7.15–7.1 (m, 2 arom. H); 4.50 (t-like, CH(2)(Pro)); 3.8–3.7 
(m, CH2(Gly)); 3.65–3.35 (m, CH2(5)(Pro)); 3.54, 3.13 (AB, JAB = 13.6, PhCH2);  2.2–2.05, 
2.05–1.8 (2m, 1:3, CH2(3), CH2(4)(Pro)); 1.55, 1.54, 1.53, 1.49, 1.35 (5s, 2 Me2C, 
Me(Phe(2Me))). 13C-NMR ((D6)DMSO): 177.2, 172.7, 171.9, 170.5, 169.8 (5s, 4 CO(amide), 
COOH); 136.9 (s, 1 arom. C); 131.0, 127.8, 126.3 (3d, 5 arom. CH); 62.5 (d, CH(2)(Pro)); 
58.1, 56.1, 55.5 (3s, 2 C(2)(Aib), C(2)(Phe(2Me))); 47.8 (t, CH2(5)(Pro)); 42.1 (t, CH2(Gly)); 
40.2 (t, PhCH2); 27.5 (t, CH2(3)(Pro)); 25.2 (t, CH2(4)(Pro)); 26.0, 24.4, 24.3, 24.0, 20.5 (5q, 
2 Me2C, Me(Phe(2Me))). ESI-MS: 526 (100, [M+Na]+).  
3.8. H-Gly-(S)-Phe(2Me)-Pro-Aib-Aib-OH ((S)-4e). 3.8.1. Z-Gly-(S)-Phe(2Me)-Pro-
Aib-Aib-OH ((S)-7e). According to GP 4, Z-Gly-(S)-Phe(2Me)-Pro-Aib-Aib-N(Me)Ph ((S)-6e, 
242 mg, 0.333 mmol) was hydrolyzed (1 h). CC (CH2Cl2/MeOH/AcOH 100:10:1): 176 mg 
(83%) of (S)-7e. Colorless solid. M.p. 134.6–137.8°. [α]D21 = –1.3 (c = 0.547, EtOH). IR 
(KBr): 3300m, 3060w, 3030w, 2980m, 2930m, 1730s, 1660s, 1610s, 1530s, 1455m, 1410m, 
1365m, 1270m, 1150m, 700m. 1H-NMR (CD3OD, 318K): 7.35–7.15 (m, 8 arom. H); 7.1–7.05 
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(m, 2 arom. H); 5.12, 5.05 (AB, JAB = 12.4, PhCH2O); 4.35–4.2 (m, CH(2)(Pro)); 4.1–3.85, 
3.8–3.5 (2m, CH2(Gly), CH2(5)(Pro)); 3.11 (A of AB, JAB = 13.4, 1 H of PhCH2); 3.1–2.85 (m, 
1 H of PhCH2); 2.2–1.95, 1.95–1.6 (2m, CH2(3), CH2(4)(Pro)); 1.44, 1.39 (2s, 1:2, 2 Me2C, 
Me(Phe(2Me))). 13C-NMR (CD3OD, 318K): 175.3, 172.3 (2 br. s, 4 CO(amide), COOH); 
158.9 (s, CO(urethane)); 138.1, 136.3 (2s, 2 arom. C); 131.6, 129.6, 129.2, 128.4 (4d, 10 
arom. CH); 68.1 (t, PhCH2O); 64.6 (d, CH(2)(Pro)); 61.8, 58.7, 58.2, (3s, 2 C(2)(Aib), 
C(2)(Phe(2Me))); 50.1 (t, CH2(5)(Pro)); 45.2, 44.0 (2t, CH2(Gly), PhCH2); 29.4, 27.2 (2t, 
CH2(3), CH2(4)(Pro)); 26.6 (br.), 25.4, 24.3 (3q, 2 Me2C, Me(Phe(2Me))). ESI-MS: 676 (11, 
[M+K]+), 660 (100, [M+Na]+).  
3.8.2. H-Gly-(R)-Phe(2Me)-Pro-Aib-Aib-OH ((S)-4e). According to GP 3, (S)-7e (184 
mg, 0.289 mmol) in MeOH (4 ml) was treated with HCO2NH4 (91 mg, 1.44 mmol) and Pd/C 
(188 mg). Crystallization from MeOH/Et2O gave 132 mg (91%) of (S)-4e). Colorless solid. 
M.p. 161.2–161.9°. [α]D21 = –62.4 (c = 0.640, H2O). IR (KBr): 3360m, 3200m, 3050m, 
3030m, 2980m, 2930m, 2870m, 1730s, 1655s, 1565s, 1535s, 1455m, 1390s, 1360m, 1310m, 
1280m, 1210m, 1195m, 1180m, 1150m, 700m. 1H-NMR ((D6)DMSO): 8.55 (br.), 8.37, 7.66, 
7.52 (4s, NH); 7.35–7.2 (m, 3 arom. H); 7.15–7.05 (m, 2 arom. H); 4.25–4.2 (m, CH(2)(Pro)); 
3.45–3.35 (m, CH2(Gly), CH2(5)(Pro)); 3.16, 3.04 (AB, JAB = 13.4, PhCH2);  2.0–1.75, 1.75–
1.6 (2m, 3:1, CH2(3), CH2(4)(Pro)); 1.33, 1.31, 1.29 (3s, 2 Me2C, Me(Phe(2Me))). 13C-NMR 
((D6)DMSO): 176.6, 172.7, 170.9, 170.6, 169.5 (5s, 4 CO(amide), COOH); 136.0 (s, 1 arom. 
C); 130.5, 127.9, 126.5 (3d, 5 arom. CH); 62.0 (d, CH(2)(Pro)); 59.0, 55.9, 55.3 (3s, 2 
C(2)(Aib), C(2)(Phe(2Me))); 47.6 (t, CH2(5)(Pro)); 42.2 (t, CH2(Gly)); 41.0 (t, PhCH2); 27.6 
(t, CH2(3)(Pro)); 25.2 (t, CH2(4)(Pro)); 25.4, 25.2, 24.8, 24.2, 22.5 (5q, 2 Me2C, 
Me(Phe(2Me))). ESI-MS: 526 (100, [M+Na]+).  
3.9. H-Gly-(R)-Phe(2Me)-Pro-Aib-Phe-OH ((R)-4f). 3.9.1. Z-Gly-(R)-Phe(2Me)-Pro-
Aib-Phe-OH ((R)-7f). The hydrolysis of Z-Gly-(R)-Phe(2Me)-Pro-Aib-Phe-OMe ((R)-6f, 862 
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mg, 1.21 mmol) with LiOH.H2O (126 mg, 3.00 mmol) in THF/MeOH/H2O (25 ml, 3:1:1) was 
carried out according to GP 1 (1.5 h): 747 mg (88%) of (R)-7f. Colorless solid. M.p. 196.2–
197.0°. [α]D21 = +123.0 (c = 0.485, EtOH). IR (KBr): 3290s, 3060m, 3030m, 2980m, 2940m, 
1730s, 1660s, 1625s, 1540s, 1500s, 1455s, 1390m, 1375m, 1290s, 1235s, 1170s, 1050m, 
735m, 700s. 1H-NMR ((D6)DMSO): 12.35 (s, COOH); 8.32 (s, NH); 7.50 (t-like, NH); 7.45–
7.05 (m, 15 arom. H, 2 NH); 5.06, 5.01 (AB, JAB = 12.6, PhCH2O); 4.45–4.35 (m, PhCH2); 
4.21 (t-like, CH(2)(Pro)); 3.85–3.6 (m, CH2(Gly), 1 H of CH2(5)(Pro)); 3.55–3.4 (m, 1 H of 
CH2(5)(Pro)); 3.41 (A of AB, JAB = 13.8, 1 H of PhCH2); 3.1–3.0 (m, 2 H of 2 PhCH2); 2.95–
2.85 (m, 1 H of PhCH2); 2.2–2.05, 1.9–1.7, 1.7–1.5 (3m, 1:2:1, CH2(3), CH2(4)(Pro)); 1.36, 
1.24, 1.21 (3s, Me2C, Me(Phe(2Me))). 13C-NMR ((D6)DMSO): 174.0, 172.4, 172.2, 171.1, 
169.2 (5s, 4 CO(amide), COOH); 156.6 (s, CO(urethane)); 137.4, 136.9, 136.8 (3s, 3 arom. 
C); 131.0, 129.1, 128.2, 127.9, 127.7, 127.6, 126.2 (7d, 15 arom. CH); 65.4 (t, PhCH2O); 62.8 
(d, CH(2)(Pro)); 58.1, 56.0 (2s, C(2)(Aib), C(2)(Phe(2Me))); 53.5 (d, CH(2)(Phe)); 47.9 (t, 
CH2(5)(Pro)); 42.7 (t, CH2(Gly)); 40.2, 37.0 (2t, 2 PhCH2); 28.2 (t, CH2(3)(Pro)); 25.3 (t, 
CH2(4)(Pro)); 26.0, 24.3, 20.3 (3q, Me2C, Me(Phe(2Me))). ESI-MS: 722 (100, [M+Na]+).  
3.9.2. H-Gly-(R)-Phe(2Me)-Pro-Aib-Phe-OH ((R)-4f). According to GP 3, (R)-7f (659 
mg, 0.942 mmol) in MeOH (20 ml) was treated with HCO2NH4 (302 mg, 4.77 mmol) and 
Pd/C (660 mg): 511 mg (96%) of (R)-4f). Colorless solid. M.p. 171.8–173.3°. [α]D21 = +111.7 
(c = 1.075, trifluoroethanol). IR (KBr): 3380s, 3340s, 3260s, 3080m, 3030m, 2980m, 2940m, 
2880m, 1680s, 1645s, 1635s, 1620s, 1615s, 1565s, 1555s, 1540s, 1515s, 1505s, 1495s, 1455s, 
1440m, 1400s, 1385s, 1360m, 1320m, 1280m, 1240m, 1210m, 1190m, 1170m, 1135m, 1100m, 
750m, 710s. 1H-NMR (CD3OD): 7.35–7.0 (m, 10 arom. H); 4.5–4.3 (m, CH(2)(Pro), 
CH(2)(Phe)); 3.85–3.6, 3.6–3.4, 3.4–3.3, 3.2–3.05 (4m, 2:2:1:3, 2 PhCH2, CH2(Gly), 
CH2(5)(Pro)); 2.15–1.9, 1.9–1.6 (2m, 1:3, CH2(3), CH2(4)(Pro)); 1.56, 1.49, 1.32 (3s, Me2C, 
Me(Phe(2Me))). 13C-NMR (CD3OD): 176.4, 174.3, 173.5, 168.8 (4s, 4 CO(amide), COOH); 
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139.2, 138.0 (2s, 2 arom. C); 132.2, 131.1, 129.3, 129.1, 127.9, 127.2 (6d, 10 arom. CH); 64.4 
(d, CH(2)(Pro)); 60.4, 58.5 (2s, C(2)(Aib), C(2)(Phe(2Me))); 57.5 (d, CH(2)(Phe)); 49.8 (t, 
CH2(5)(Pro)); 42.1, 41.9, 39.0 (3t, CH2(Gly), 2 PhCH2); 29.2 (t, CH2(3)(Pro)); 26.6 (t, 
CH2(4)(Pro)); 27.4, 24.3, 21.3 (3q, 2 Me2C, Me(Phe(2Me))). ESI-MS: 588 (5, [M+Na]+), 566 
(100, [M+1]+). 
3.10. H-Gly-(S)-Phe(2Me)-Pro-Aib-Phe-OH ((S)-4f). 3.10.1. Z-Gly-(S)-Phe(2Me)-
Pro-Aib-Phe-OH ((S)-7f). The hydrolysis of Z-Gly-(S)-Phe(2Me)-Pro-Aib-Phe-OMe ((S)-6f, 
120 mg, 0.167 mmol) with LiOH.H2O (18 mg, 0.429 mmol) in THF/MeOH/H2O (2 ml, 3:1:1) 
was carried out according to GP 1 (1.5 h): 109 mg (93%) of (S)-7f. Colorless solid. M.p. 
92.0–93.1°. [α]D21 = –18.2 (c = 0. 125, EtOH). IR (KBr): 3300s, 3060m, 3030m, 2980m, 
2930m, 1730s, 1715s, 1670s, 1660s, 1635s, 1550s, 1540s, 1520s, 1505s, 1455s, 1410m, 
1370m, 1310m, 1240s, 1165m, 1050m, 740m, 700m. 1H-NMR (CDCl3): 7.79 (s, NH); 7.45 (d, 
J = 8.1, NH); 7.4–7.05 (m, 15 arom. H); 7.02 (s, NH); 5.67 (br. s, NH); 5.18, 5.11 (AB, JAB = 
12.2, PhCH2O); 4.85–4.7 (m, PhCH2); 4.31 (t-like, CH(2)(Pro)); 3.95–3.7 (ABX, JAB = 17.2, 
CH2(Gly)); 3.6–3.45, 3.35–3.1, 3.05–2.9 (3m, 1:2:3, 2 PhCH2, CH2(5)(Pro)); 2.35–2.2, 1.95–
1.8, 1.7–1.5 (3m, 1:1:2, CH2(3), CH2(4)(Pro)); 1.48, 1.45, 1.20 (3s, Me2C, Me(Phe(2Me))). 
13C-NMR (CDCl3): 175.4, 173.8, 173.5, 172.1, 169.7 (5s, 4 CO(amide), COOH); 157.0 (s, 
CO(urethane)); 137.3, 136.1, 134.2 (3s, 3 arom. C); 130.2, 129.0, 128.8, 128.6, 128.5, 128.3, 
128.2, 127.9, 126.6 (9d, 15 arom. CH); 67.3 (t, PhCH2O); 64.1 (d, CH(2)(Pro)); 60.2, 57.0 
(2s, C(2)(Aib), C(2)(Phe(2Me))); 54.6 (d, CH(2)(Phe)); 49.1 (t, CH2(5)(Pro)); 44.8 (t, 
CH2(Gly)); 43.3, 36.9 (2t, 2 PhCH2); 28.4 (t, CH2(3)(Pro)); 26.2 (t, CH2(4)(Pro)); 26.5, 24.2, 
23.4 (3q, Me2C, Me(Phe(2Me))). ESI-MS: 722 (100, [M+Na]+).  
3.10.2. H-Gly-(S)-Phe(2Me)-Pro-Aib-Phe-OH ((S)-4f). According to GP 3, a 
suspension of (S)-7f (106 mg, 0.151 mmol) in MeOH (2 ml) was treated with H2 in the 
presence of Pd/C (10 mg) for 44.5 h. Addition of CH2Cl2 and filtration gave 74 mg (86%) of 
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(S)-4f). Colorless solid. M.p. 166.5–167.8°. [α]D21 = –0.7 (c = 0.420, trifluoroethanol). 1H-
NMR (CD3OD): 7.35–7.15 (m, 8 arom. H); 7.1–7.05 (m, 2 arom. H); 4.6–4.55, 4.4–4.3 (2m, 
CH(2)(Pro), CH(2)(Phe)); 3.85–3.7, 3.6–3.45, 3.35–3.05 (3m, 1:1:2, 2 PhCH2, CH2(Gly), 
CH2(5)(Pro)); 2.2–2.05, 2.05–1.9, 1.9–1.7 (3m, 1:1:2, CH2(3), CH2(4)(Pro)); 1.45, 1.44, 1.40 
(3s, Me2C, Me(Phe(2Me))). 13C-NMR (CD3OD): 176.9, 174.4, 172.9, 166.6 (4s, 4 
CO(amide), COOH); 138.8, 137.1 (2s, 2 arom. C); 131.8, 130.4, 129.4, 128.1, 127.7 (5d, 10 
arom. CH); 64.1 (d, CH(2)(Pro)); 61.5, 58.1 (2s, C(2)(Aib), C(2)(Phe(2Me))); 55.8 (d, 
C(2)(Phe)); 49.9 (t, CH2(5)(Pro)); 42.8, 41.1, 38.6 (3t, CH2(Gly), 2 PhCH2); 29.3, 27.0 (2t, 
CH2(3)(Pro), CH2(4)(Pro)); 26.2, 25.1, 23.2 (3q, Me2C, Me(Phe(2Me))).  
4. Cyclization of Pentapeptides 4. 4.1. Cyclo(Gly-Aib-(R,S)-Phe(2Me)-Aib-Gly) (5b). 
a) A soln. of 4b (30 mg, 0.065 mmol) in DMF (40 ml) was cooled to 0°. Then, a soln. of 
DPPA (27 mg, 0.098 mmol) in DMF (1 ml) was added slowly within 2.5 h (syringe). After 
addition of NaHCO3 (27 mg), the mixture was stirred for 63 h at 0°. Evaporation of DMF 
(HV), filtration through XAD resin (type 2, 100–200 µm), and HPLC (72% H2O/0.1% TFA; 
28% MeCN/0.1% TFA, 8 ml/min; 220 nm; Rt = 14.4 min) gave 13 mg (45%) of 5b. 
 b) To a soln. of 4b (21 mg, 0.045 mmol) in DMF (40 ml) were added HOBt (19 mg, 
0.141 mmol), TBTU (45 mg, 0.140 mmol), and DIEA (0.4 ml), and the mixture was stirred at 
r.t. for 3 h. Then, DMF was evaporated (HV) and the residue purified by HPLC: 13 mg (64%) 
of 5b. Colorless solid. M.p. 286–288°. Rf = 0.1 (SiO2, CH2Cl2/MeOH 10:1). IR (KBr): 3510m, 
3480m, 3350s, 3310s, 3040w, 2980w, 1680s, 1665s, 1640s, 1550s, 1515s, 1470m, 1440m, 
1390m, 1365m, 1290m, 1265m, 1215m, 1205m, 1180m, 745m, 700m. 1H-NMR ((D6)DMSO): 
9.04, 8.76 (2s, 2 NH); 7.95–7.85 (m, NH); 7.55 (s, NH); 7.25–7.15 (m, 3 arom. H); 7.0–6.95 
(m, 2 arom. H); 6.90 (d, J = 9.7, NH); 4.15–4.0 (m, CH2(Gly)); 3.3–3.15 (m, CH2(Gly), 1 H of 
PhCH2); 2.90 (B of AB, JAB = 13.3, 1 H of PhCH2); 1.72, 1.40, 1.37, 1.29, 1.24 (5s, 2 Me2C, 
Me(Phe(2Me)). 1H-NMR (CD3OD): 8.05–7.95 (m, NH); 7.83 (s, NH); 7.25 (d, J = 10.2, NH); 
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7.25–7.15 (m, 3 arom. H); 7.1–7.0 (m, 2 arom. H); 4.35–4.2 (m, CH2(Gly)); 3.55–3.3 (m, 
CH2(Gly), 1 H of PhCH2);  3.12 (B of AB, JAB = 13.6, 1 H of PhCH2); 1.83, 1.50, 1.47, 1.36 
(4s, 1:2:1:1, 2 Me2C, Me(Phe(2Me)).  13C-NMR (CD3OD): 177.1, 176.7, 175.2, 172.1, 171.0 
(5s, 5 CO(amide)); 137.4 (s, arom. C); 131.1, 129.0, 128.1 (3d, 5 arom. CH); 62.0, 59.5, 59.1 
(3s, 2 C(2)(Aib), C(2)(Phe(2Me))); 44.3, 44.0, 43.5  (3t, 2 CH2(Gly), PhCH2); 26.6, 26.3, 
25.1, 24.7, 24.0 (5q, 2 Me2C, Me(Ph(2Me))). ESI-MS: 486 (100, [M+Na]+).  
Suitable crystals for the X-ray crystal-structure determination were grown from 
MeOH/H2O by slow evaporation of the solvent. 
4.2. Cyclo(Gly-(R,S)-Phe(2Me)-Gly-Aib-Aib) (5c). Cyclization of 4c (52.5 mg, 0.113 
mmol) with DEPC (43 mg, 0.264 mmol) and DIEA (0.75 ml) in DMF (75 ml) according to 
GP 5 gave 45.9 mg (91%) of 5c. Colorless solid. M.p. 143.3–145.2°. Rf = 0.2 (SiO2, 
CH2Cl2/MeOH 10:1). IR (KBr): 3320s, 3060m, 3030m, 2980m, 2930m, 1690s, 1680s, 1660s, 
1650s, 1545s, 1455m, 1445m, 1385m, 1365m, 1270m, 1225m, 1195m, 700m. 1H-NMR 
((D6)DMSO): 8.32, 8.00 (2s, 2 NH); 7.59 (t-like, NH); 7.51 (s, NH); 7.37 (t-like, NH); 7.35–
7.2 (m, 3 arom. H); 7.1–7.05 (m, 2 arom. H); 3.91 (dd, J = 16.0, 6.7, 1 H  of CH2(Gly)); 3.81 
(dd, J = 15.0, 6.3, 1 H  of CH2(Gly)); 3.60 (dd, J = 15.0, 3.8, 1 H  of CH2(Gly)); 3.46 (dd, J = 
16.0, 3.8, 1 H of CH2(Gly)); 3.31, 2.91 (AB, JAB = 13.3, PhCH2); 1.45, 1.42, 1.41, 1.37, 1.15 
(5s, 2 Me2C, Me(Phe(2Me))). 13C-NMR ((D6)DMSO): 174.7, 174.1, 173.2, 169.3, 169.0 (5s, 
5 CO(amide)); 136.9 (s, 1 arom. C); 130.5, 127.8 126.2 (3d, 5 arom. CH); 59.3, 57.0, 56.9 (3s, 
2 C(2)(Aib), C(2)(Phe(2Me))); 42.9, 42.7, 39.8 (3t, 2 CH2(Gly), PhCH2); 25.9, 25.1, 24.9, 
24.2, 22.5 (5q, 2 Me2C, Me(Phe(2Me))). ESI-MS: 484 (20, [M+K]+), 468 (100, [M+Na]+), 446 
(37, [M+1]+). 
4.3. Cyclo(Gly-(R)-Phe(2Me)-Gly-Aib-Phe) ((R)-5d). a) To a soln. of (R)-4d (18.7 mg, 
0.036 mmol) in DMF (30 ml) were added HOBt (17 mg, 0.126 mmol), TBTU (37 mg, 0.115 
mmol), and DIEA (0.3 ml), and the mixture was stirred at r.t. for 3 h. Then, DMF was 
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removed by distillation and the residue dissolved in AcOEt (10 ml). This soln. was extracted 
with 5% aq. KHSO4 soln. (3×), 5% aq. NaHCO3 soln. (3×), and sat. aq. NaCl soln., dried 
(Na2SO4), and purified by HPLC (65% H2O/0.1% TFA; 35% MeCN/0.1% TFA, 8 ml/min; 
220 nm; Rt = 27.6 min): 11.6 mg (64%) of (R)-5d.  
b) Cyclization of (R)-4d (18.8 mg, 0.036 mmol) with DEPC (22 mg, 0.135 mmol) and 
DIEA (0.3 ml) in DMF (30 ml) was performed according to GP 5. The residue was dissolved 
in AcOEt (10 ml) and treated as in the previous experiment: 11.1 mg (61%) of (R)-5d. 
Colorless solid. M.p. 261.0–262.3°. Rf = 0.2 (SiO2, CH2Cl2/MeOH 10:1). [α]D21 = +21.8 (c = 
0.195, EtOH). IR (KBr): 3350s, 3310s, 3280s, 3060m, 3030m, 2990m, 2930m, 1690s, 1680s, 
1670s, 1660s, 1650s, 1645s, 1550m, 1540m, 1530m, 1520m, 1505m, 1500m, 1465m, 1445m, 
1435m, 1390m, 1365m, 1280m, 1260m, 1210m, 1200m, 1175m, 1130m, 745m, 700m. 1H-
NMR ((D6)DMSO): 8.49, 8.43 (2s, 2 NH); 7.75 (t-like, NH); 7.71 (d, J = 9.1, NH); 7.3–7.1 
(m, 10 arom. H); 4.65–4.5 (m, CH(2)(Phe)); 3.92 (dd, J = 13.9, 6.6, 1H of CH2(Gly)); 3.83 
(dd, J = 15.5, 5.8, 1 H of CH2(Gly)); 3.63 (dd, J = 15.9, 3.6, 1H of CH2(Gly)); 3.46 (dd, J = 
13.9, 3.8, 1H of CH2(Gly)); 3.34 (d, J = 13.4, 1 H of PhCH2(Phe(2Me))); 3.20 (dd, J = 13.9, 
4.2, 1 H of PhCH2(Phe)); 2.95 (d, J = 13.3, 1 H of PhCH2(Phe(2Me))); 2.77 (dd, J = 13.9, 
10.5, 1 H of PhCH2(Phe)); 1.19, 1.15, 1.13 (3s, 2 Me2C, Me(Phe(2Me)). 13C-NMR 
((D6)DMSO): 173.8, 173.4, 171.7, 169.0 (4s, 5 CO(amide)); 138.3, 136.6 (2s, 2 arom. C); 
130.5, 129.1, 127.8, 126.3, 126.0 (5d, 10 arom. CH); 59.8, 56.1 (2s, C(2)(Aib), 
C(2)(Phe(2Me))); 53.2 (d, CH(2)(Phe)); 42.9, 41.6, 39.9, 36.6  (4t, 2 CH2(Gly), 2 PhCH2); 
25.3, 23.6, 22.1 (3q, Me2C, Me(Ph(2Me))). APCI-MS: 508 ([M+1]+). 
4.4. Cyclo(Gly-(S)-Phe(2Me)-Gly-Aib-Phe) ((S)-5d). To a soln. of (S)-4d (29.5 mg, 
0.056 mmol) in DMF (45 ml) were added HOBt (24 mg, 0.178 mmol), TBTU (55 mg, 0.171 
mmol), and DIEA (0.45 ml), and the mixture was stirred at r.t. over night. Then, DMF was 
evaporated (HV), and the residue was purified by CC (CH2Cl2/MeOH 10:1) and PLC 
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(CH2Cl2/MeOH 10:1): 15.8 mg (55%) of (S)-5d. Colorless solid. M.p. 162.5–164.3°. Rf = 0.4 
(SiO2, CH2Cl2/MeOH 10:1). [α]D21 = –89.1 (c = 0.430, EtOH). IR (KBr): 3300s, 3060m, 
3030m, 2980m, 2930m, 1695s, 1680s, 1670s, 1660s, 1650s, 1645s, 1555s, 1540s, 1530s, 
1515s, 1495s, 1470m, 1460m, 1455m, 1445m, 1390m, 1370m, 1320m, 1260m, 1230m, 1180m, 
1130m, 1080m, 740m, 700m. 1H-NMR ((D6)DMSO): 8.66, 8.53 (2s, 2 NH); 8.08 (d, J = 9.3, 
NH); 7.35–7.05 (m, 10 arom. H, 2 NH); 4.7–4.55 (m, CH(2)(Phe)); 4.15 (dd, J = 14.0, 9.2, 1H 
of CH2(Gly)); 4.01 (dd, J = 16.6, 5.8, 1 H of CH2(Gly)); 3.55–3.35 (m, 2H of 2 CH2(Gly), 1 H 
of PhCH2(Phe(2Me)), 1 H of PhCH2(Phe)); 2.88 (d, J = 13.5, 1 H of PhCH2(Phe(2Me))); 
2.85–2.7 (m, 1 H of PhCH2(Phe)); 1.17, 1.15, 1.01 (3s, 2 Me2C, Me(Phe(2Me)). 13C-NMR 
((D6)DMSO): 175.0, 173.5, 171.7, 169.8, 169.7 (5s, 5 CO(amide)); 139.2, 137.6 (2s, 2 arom. 
C); 131.0, 129.6, 128.21, 128.15, 126.6, 126.3 (6d, 10 arom. CH); 60.0, 56.5 (2s, C(2)(Aib), 
C(2)(Phe(2Me))); 53.7 (d, CH(2)(Phe)); 42.5, 42.2, 39.0, 36.0  (4t, 2 CH2(Gly), 2 PhCH2); 
26.1, 23.9, 22.8 (3q, Me2C, Me(Ph(2Me))). APCI-MS: 508 ([M+1]+). 
4.5. Cyclo(Gly-(R,S)-Phe(2Me)-Pro-Aib-Aib) (5e). Cyclization of 4e (22.0 mg, 0.044 
mmol) with DEPC (22.0 mg, 0.135 mmol) and DIEA (0.25 ml) in DMF (25 ml) was 
performed according to GP 5. After PLC (CH2Cl2/MeOH 10:1), 15.4 mg (73%) of 5e were 
obtained. 
4.6. Cyclo(Gly-(R)-Phe(2Me)-Pro-Aib-Aib) ((R)-5e). Cyclization of (R)-4e (33.5 mg, 
0.067 mmol) with DEPC (33.7 mg, 0.207 mmol) and DIEA (0.45 ml) in DMF (45 ml) was 
performed according to GP 5. After PLC (CH2Cl2/MeOH 10:1), 25.2 mg (78%) of (R)-5e 
were obtained. Colorless solid. M.p. 142.6–143.6°. Rf = 0.4 (SiO2, CH2Cl2/MeOH 10:1). 
[α]D21 = +25.0 (c = 0.56, EtOH). IR (KBr): 3300s, 3030m, 2940m, 2915m, 1695s, 1680s, 
1670s, 1660s, 1650s, 1645s, 1635s, 1555s, 1540s, 1530s, 1515s, 1505s, 1495m, 1470m, 
1465m, 1455m, 1390m, 1365m, 1305m, 1265m, 1240m, 1215m, 1190m, 1130m, 1050m, 
740w, 705m. 1H-NMR ((D6)DMSO): 8.3 (br. s, NH); 7.80 (s, NH); 7.35–7.2 (m, 3 arom. H, 1 
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NH); 7.1–7.0 (m, 2 arom. H); 6.85 (br. s, NH); 4.6–4.5 (m, CH(2)(Pro)); 4.03 (dd, J = 16.6, 
7.2, 1H of CH2(Gly)); 3.55–3.35 (m, 1 H of CH2(Gly), CH2(5)(Pro), 1 H of PhCH2); 2.92 (br. 
d, J = 12.4, 1 H of PhCH2); 2.0–1.7 (m, CH2(3), CH2(4)(Pro)); 1.52, 1.46, 1.45, 1.30, 1.23 (5s, 
2 Me2C, Me(Phe(2Me)). 13C-NMR ((D6)DMSO): 175.5, 174.0 (2s, 2 CO(Aib)); 171.7 (s, 
CO(Phe(2Me))); 170.0, 169.4 (2s, CO(Pro), CO(Gly)); 137.1 (s, 1 arom. C); 130.8, 127.8, 
126.2 (3d, 5 arom. CH); 61.5 (d, CH(2)(Pro)); 58.4 (s, C(2)(Phe(2Me))); 57.5, 57.0 (2s, 2 
C(2)(Aib)); 46.4 (t, CH2(5)(Pro));  41.8 (t, CH2(Gly)); 39.9 (t, PhCH2); 26.6, 24.2 (2t, CH2(3), 
CH2(4)(Pro)); 24.5, 24.3, 23.3, 22.7 (4q, 2 Me2C); 19.1 (q, Me(Ph(2Me))). ESI-MS: 508 
([M+1]+). 
4.7. Cyclo(Gly-(S)-Phe(2Me)-Pro-Aib-Aib) ((S)-5e). Cyclization of (S)-4e (27.0 mg, 
0.054 mmol) with DEPC (38.0 mg, 0.233 mmol) and DIEA (0.35 ml) in DMF (35 ml) was 
performed according to GP 5. After PLC (CH2Cl2/MeOH 10:1), 11.9 mg (46%) of (S)-5e 
were obtained. Colorless solid. M.p. 145.5–147.1°. Rf = 0.4 (SiO2, CH2Cl2/MeOH 10:1). 
[α]D21 = –45.5 (c = 0.38, EtOH). IR (KBr): 3300s, 3040w, 2980w, 1695s, 1690m, 1660s, 
1650s, 1635s, 1555m, 1550m, 1540m, 1530m, 1520m, 1505m, 1470m, 1465m, 1455m, 1445m, 
1390m, 1385m, 700m. 1H-NMR ((D6)DMSO): 7.82 (br. s, NH); 7.35–7.15 (m, 3 arom. H, 1 
NH); 7.15–7.05 (m, 2 arom. H); 4.45–4.4 (m, CH(2)(Pro)); 4.2–3.15 (m, CH2(Gly), 
CH2(5)(Pro), PhCH2); 2.1–1.8 (m, CH2(3), CH2(4)(Pro)); 1.46, 1.44, 1.40, 1.33, 1.27 (5s, 2 
Me2C, Me(Phe(2Me)). 13C-NMR ((D6)DMSO, 350K): 174.9, 174.5, 170.9, 169.4 (4s, 5 
CO(amide)); 135.8 (s, 1 arom. C); 130.4, 127.8, 126.5 (3d, 5 arom. CH); 61.2 (d, 
CH(2)(Pro)); 60.9, 57.3, 57.2 (3s, C(2)(Phe(2Me)), 2 C(2)(Aib)); 47.5 (t, CH2(5)(Pro));  42.6, 
41.6 (2t, CH2(Gly), PhCH2); 24.7, 24.3, 23.7, 23.5, 22.7 (5q, 2 Me2C, Me(Ph(2Me))) (CH2(3), 
CH2(4)(Pro) could not be detected). ESI-MS: 508 ([M+1]+). 
4.8. Cyclo(Gly-(R)-Phe(2Me)-Pro-Aib-Phe) ((R)-5f). Cyclization of (R)-4f (42 mg, 
0.074 mmol) with DEPC (29 mg, 0.178 mmol) and DIEA (0.5 ml) in DMF (50 ml) was 
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performed according to GP 5. The residue was dissolved in CH2Cl2 and the soln. was 
extracted with 5% aq. KHSO4 soln. (3×), 5% aq. NaHCO3 soln. (3×), and sat. aq. NaCl soln., 
dried (Na2SO4), and filtered through cotton. PLC (AcOEt/MeOH 10:1) and crystallization 
from MeOH/AcOEt/hexane gave 19.2 mg (47%) of (R)-5f. Colorless solid. M.p. 250.3–
153.1°. Rf = 0.5 (SiO2, CH2Cl2/MeOH 10:1). [α]D21 = +42.5 (c = 0.595, EtOH). IR (KBr): 
3300m, 3020w, 2940w, 1695s, 1680s, 1630s, 1540m, 1530s, 1520m, 1505m, 1495m, 1470m, 
1465m, 1450m, 1415m, 1400m, 1380m, 700m. 1H-NMR (CDCl3): 7.63 (d, J = 9.2, NH(Phe)); 
7.2–7.1 (m, 8 arom. H); 7.08 (s, NH(Aib)); 6.9–6.85 (m, 2 arom. H); 6.85–6.8 (m, NH(Gly)); 
6.30 (s, NH(Phe(2Me))); 4.86 (dd, J = 7.7, 1.5, CH(2)(Pro)); 4.7–4.6 (q-like, CH(2)(Phe)); 
4.02 (dd, J = 15.9, 9.7, 1H of CH2(Gly)); 3.62 (d, J = 14.0, 1 H of PhCH2(Phe(2Me)); 3.6–
3.55, 3.55–3.45 (2m, CH2(5)(Pro)); 3.04 (dd, J = 13.7, 8.9, 1 H of PhCH2(Phe));  2.89 (d, J = 
13.9, 1 H of PhCH2(Phe(2Me))); 2.84 (dd, J = 13.7, 6.7, 1 H of PhCH2(Phe)); 2.76 (dd, J = 
15.9, 3.5, CH2(Gly)); 2.3–2.2, 2.1–2.0, 1.95–1.85, 1.75–1.65 (4m, CH2(3), CH2(4)(Pro)); 1.55, 
1.24 (2s, Me2C); 1.23 (s, Me(Phe(2Me)). 13C-NMR (CDCl3): 176.5 (s, CO(Aib)); 173.9 (s, 
CO(Phe)); 173.14 (s, CO(Pro)); 173.06 (s, CO(Phe(2Me))); 168.8 (s, CO(Gly)); 136.94, 
136.88 (2s, 2 arom. C); 131.1, 129.2, 128.5, 128.0, 126.8, 126.7 (6d, 10 arom. CH); 61.4 (d, 
CH(2)(Pro)); 59.0 (s, C(2)(Phe(2Me))); 58.8 (s, C(2)(Aib)); 54.1 (d, CH(2)(Phe)); 46.8 (t, 
CH2(5)(Pro));  42.3 (t, CH2(Gly)); 40.4 (t, PhCH2(Phe(2Me))); 35.6 (t, PhCH2(Phe)); 25.5, 
25.4 (2t, CH2(3), CH2(4)(Pro)); 25.1, 24.7 (2q, Me2C); 19.9 (q, Me(Ph(2Me))). ESI-MS: 570 
([M+Na]+). Anal. calc. for C30H37N5O5.1.5 H2O (574.64): C 62.70, H 7.02, N 12.19; found C 
62.94, H 6.71, N 11.97. 
Suitable crystals for the X-ray crystal-structure determination were grown from 
AcOEt/MeOH/hexane by slow evaporation of the solvent. 
4.9. Cyclo(Gly-(S)-Phe(2Me)-Pro-Aib-Phe) ((S)-5f). Cyclization of (S)-4f (22.5 mg, 
0.040 mmol) with DEPC (12 mg, 0.074 mmol) and DIEA (0.2 ml) in DMF (20 ml) was 
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carried out according to GP 5. After PLC (CH2Cl2/MeOH 10:1) and CC (CH2Cl2/MeOH/NH3 
20:1:0.1), 2.2 mg (10%) of (S)-5f were obtained. Colorless solid. M.p. 174.0–177.5°. Rf = 
0.45 (SiO2, CH2Cl2/MeOH 10:1). 1H-NMR (CDCl3): 7.79 (d, J = 6.9, NH); 7.4–7.15 (m, 10 
arom. H, 1 NH); 6.65–6.55 (m, NH); 5.87 (s, NH); 5.01 (d, J = 6.0, CH(2)(Pro)); 4.7–4.65 (m, 
CH(2)(Phe)); 4.2–4.1 (m, 1 H of CH2(Gly)); 3.8–3.65 (m, CH2(5)(Pro)); 3.2–3.15 (m, 1 H of 
PhCH2(Phe)); 3.1–2.95 (m, PhCH2(Phe(2Me)), 1 H of CH2(Gly)); 2.95–2.9 (m, 1 H of 
PhCH2(Phe)); 2.45–2.35, 2.25–2.15, 2.1–2.0, 1.8–1.7 (4m, CH2(3), CH2(4)(Pro)); 1.64, 1.52, 
1.45 (3s, Me2C, Me(Phe(2Me)). 13C-NMR (CDCl3): 176.2, 173.6, 172.7, 171.9, 168.3 (5s, 5 
CO(amide)); 136.9, 134.0 (2s, 2 arom. C); 130.1, 129.2, 129.0, 128.4, 127.9, 126.7 (6d, 10 
arom. CH); 61.1 (d, CH(2)(Pro)); 60.3, 58.7 (2s, C(2)(Phe(2Me)), C(2)(Aib)); 53.8 (d, 
CH(2)(Phe)); 46.9 (t, CH2(5)(Pro));  42.5 (t, CH2(Gly)); 41.3 (t, PhCH2(Phe(2Me))); 35.2 (t, 
PhCH2(Phe)); 25.49, 24.8 (2t, CH2(3), CH2(4)(Pro)); 25.52, 24.6, 23.2 (3q, Me2C, 
Me(Ph(2Me))). ESI-MS: 570 ([M+Na]+). 
4. X-Ray Crystal-Structure Determination of 5b and (R)-5f (see Table 6 and Figs. 1 
and 2)6). The measurements were made using graphite-monochromated MoKα radiation 
(λ  0.7107 Å) on a Rigaku AFC5R diffractometer fitted to a 12 kW rotating-anode generator. 
The data of 5b were collected at 283 K because cooling the crystals to a lower temperature 
destroyed the crystals. The intensities were corrected for Lorentz and polarization effects. In 
the case of 5b, azimuthal scans of several reflections indicated no need for an absorption 
correction, whereas in the case of (R)-5f an empirical absorption correction, based on 
azimuthal scans of several reflections [38], was applied. Equivalent reflections, other than 
Friedel pairs, were merged. The data collection and refinement parameters are given in Table 
6)  CCDC-1024796–1024797 contain the supplementary crystallographic data for this 
paper. These data can be obtained free of charge from The Cambridge Crystallographic 
Data Centre via www.ccdc.cam.ac.uk/data_request/cif. 
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6, and views of the molecules are shown in Figs. 1 and 2. The structures were solved by direct 
methods using SHELXS86 [39] for 5b, which revealed the positions of all non-H-atoms, and 
SnB [40] for (R)-5f, which revealed the positions of most of the non-H-atoms. In the latter 
case, the remaining non-H atoms were located in a subsequent difference electron density 
map. For both structures, the non-H-atoms were refined anisotropically. 
In the case of 5b, the asymmetric unit contains two molecules of the peptide plus one 
H2O molecule. The Ph ring in both molecules is disordered due to in-plane waggling of the 
ring about the ipso C–C bond. Two sets of positions were defined for the atoms of each 
disordered Ph ring and the site occupation factors of the major conformations of these groups 
refined to 0.52(4) and 0.55(3) for molecules A and B, respectively. Similarity restraints were 
applied to the chemically equivalent bond lengths and angles involving all disordered C-
atoms, while neighboring atoms within and between each conformation of the disordered Ph 
rings were lightly restrained to have similar atomic displacement parameters.  
In the case of (R)-5f, the asymmetric unit contains two molecules of the peptide, as 
well as sites for disordered MeOH and/or H2O molecules. The disordered solvent molecules 
could not be identified or modelled adequately, so the SQUEEZE routine [41] of the program 
PLATON [42] was employed. When the solvent molecules are omitted from the model, each 
unit cell contains two cavities of 427 Å3 and four cavities of 63 Å3. The electron count in the 
unit cell was calculated to be approximately 198 e. One MeOH molecule has 24 e, so it has 
been assumed that there are 8 MeOH molecules per unit cell, although it is possible that some 
of these might be H2O. This approximation has been used in the subsequent calculation of the 
empirical formula, formula weight, density, linear absorption coefficient and F(000). Based 
on the assumption, the ratio of peptide to MeOH molecules in the structure is 1:1. 
One of the peptide molecules (molecule B) has disorder of two atoms in the 
5-membered ring due to an alternating ring conformation. Two sets of positions were defined 
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for these atoms and the site occupation factor of the major conformation refined to 0.588(10). 
Similarity restraints were applied to the chemically equivalent bond lengths and angles 
involving all disordered C-atoms and the C–C bond lengths in the disordered region were 
restrained to 1.520(5) Å. Neighboring atoms within and between each conformation of the 
disordered group were restrained to have similar atomic displacement parameters. The same 
peptide molecule also shows evidence for slight conformational disorder of the peptide chain 
from C(45) to C(48), as well as in the Ph rings, but no attempt was made to model this 
additional disorder. Molecule A shows no evidence for disorder. The amide H-atoms in (R)-5f 
and the H2O H-atoms in 5b were placed in the positions indicated by a difference electron 
density map and their positions were allowed to refine together with individual isotropic 
displacement parameters while restraining the O–H distances in the H2O molecule to 0.84(2) 
Å. All remaining H-atoms in each structure were placed in geometrically calculated positions 
and refined by using a riding model where each H-atom was assigned a fixed isotropic 
displacement parameter with a value equal to 1.2Ueq of its parent C-atom (1.5Ueq for the Me 
groups).  
The refinement of each structure was carried out on F2 by using full-matrix least-
squares procedures, which minimized the function Σw(Fo2 – Fc2)2. A correction for secondary 
extinction was not applied. In the case of (R)-5f, one reflection, whose intensity was 
considered to be an extreme outlier, was omitted from the final refinement. The enantiomer 
used in the refinement was based on the known S-configuration at C(6) and C(15). Neutral 
atom scattering factors for non-H-atoms were taken from [43], and the scattering factors for 
H-atoms were taken from [44].  Anomalous dispersion effects were included in Fc [45]; the 
values for ƒ’ and ƒ” were those of [46].  The values of the mass attenuation coefficients are 
those of [47].  All refinements were performed using SHELXL-2014 [48]. 
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Table 6.  Crystallographic Data for Compounds 5b and (R)-5f 
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Legends 
 
Fig. 1. ORTEP Plot [31] of the molecular structure of the two symmetry-independent 
molecules A (with (R)-Phe(2Me)) and B (with (S)-Phe(2Me)) of cyclopentapeptide 5b (50% 
probability ellipsoids, arbitrary numbering of atoms, H-atoms bonded to C-atoms and minor 
component of the disordered Ph ring in each molecule omitted for clarity) 
 
Fig. 2. ORTEP Plot [31] of the molecular structure of the two symmetry-independent 
molecules A and B of cyclopentapeptide (R)-5f (50% probability ellipsoids, arbitrary numbering 
of atoms, H-atoms bonded to C-atoms and one component of the disordered five-membered ring 
in molecule B omitted for clarity) 
 
Fig. 3. Dependence of the chemical shifts of the NH resonances of (R)-5f as a function of 
the (D6)DMSO concentration (% v/v) in CDCl3 
 
Fig. 4. a) Observed NOE Signals of (R)-5f in CDCl3; b) Proposed all-trans Conformation 
of (R)-5f in CDCl3 Solution 
 
 
Table 1. Linear Phe(2Me) and Aib-Containing Pentapeptides 
 
Table 2. Cyclization of Pentapeptides 4 leading to Cyclopentapeptides 5 
 
Table 3.  Intra- and Intermolecular H-Bonds of 5b and (R)-5f (atom numbering refers to 
Figs. 1 and 2) 
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Table 4. Selected Torsion Angles φ, ψ, and ω of the Backbone of the Cyclopentapeptides 
5a [14c] and 5b in the Crystal  
 
Table 5. Selected Torsion Angles (°) φ, ψ, and ω of the Backbone of the Cyclopentapeptide 
(R)-5f in the Crystal  
 
Table 6.  Crystallographic Data for Compounds 5b and (R)-5f 
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Table 1. Linear Phe(2Me) and Aib-Containing Pentapeptides 
 
 
Pentapeptide 
 
6 (X = Z) [26] 
 
7 (X = Z, Y = OH) 
 
4 (X = H, Y = OH) 
 
X-Gly-Aib-(R,S)-Phe(2Me)-Aib-Gly-Y  
X-Gly-(R,S)-Phe(2Me)-Gly-Aib-Aib-Y  
X-Gly-(R,S)-Phe(2Me)-Gly-Aib-Phe-Y 
X-Gly-(R)-Phe(2Me)-Gly-Aib-Phe-Y  
X-Gly-(S)-Phe(2Me)-Gly-Aib-Phe-Y  
X-Gly-(R,S)-Phe(2Me)-Pro-Aib-Aib-Y  
X-Gly-(R)-Phe(2Me)-Pro-Aib-Aib-Y  
X-Gly-(S)-Phe(2Me)-Pro-Aib-Aib-Y  
X-Gly-(R)-Phe(2Me)-Pro-Aib-Phe-Y  
X-Gly-(S)-Phe(2Me)-Pro-Aib-Phe-Y  
 
 
6a Y = MeO 
6c Y = Ph(Me)N 
6d Y = BnO 
(R)-6d’ Y = MeO 
(S)-6d’ Y = MeO 
6e Y = Ph(Me)N 
(R)-6e Y = Ph(Me)N 
(S)-6e Y = Ph(Me)N 
(R)-6f Y = MeO 
(S)-6f Y = MeO 
 
 
7a (85%) 
7c (98%) 
- 
(R)-7d (94%) 
(S)-7d (97%) 
7e (81%) 
(R)-7e (82%) 
(S)-7e (83%) 
(R)-7f (88%) 
(S)-7f (93%) 
 
4b (86%) 
4c (94%) 
4d (99%) 
(R)-4d (quant.) 
(S)-4d (97%) 
4e (96%) 
(R)-4e (95%) 
(S)-4e (91%) 
(R)-4f (96%) 
(S)-4f (86%) 
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Table 2. Cyclization of Pentapeptides 4 leading to Cyclopentapeptides 5 
 
 
Linear Penta- 
Peptides 4  
 
 
Cyclization Conditions 
 
Cyclopentapeptides 5 
 
Yield (%) 
 
4b 
 
4c 
(R)-4d 
 
(S)-4d 
4e 
(R)-4e 
(S)-4e 
(R)-4f 
(S)-4f 
 
DPPA/NaHCO3, DMF, 0° 
TBTU/HOBt/DIEA, DMF, r.t. 
DEPC/DIEA, DMF, r.t. 
TBTU/HOBt/DIEA, DMF, r.t. 
DEPC/DIEA, DMF, r.t. 
TBTU/HOBt/DIEA, DMF, r.t. 
DEPC/DIEA, DMF, r.t. 
DEPC/DIEA, DMF, r.t. 
DEPC/DIEA, DMF, r.t. 
DEPC/DIEA, DMF, r.t. 
DEPC/DIEA, DMF, r.t. 
 
5b        cyclo(Gly-Aib-(R,S)-Phe(2Me)-Aib-Gly)  
 
5c        cyclo(Gly-(R,S)-Phe(2Me)-Gly-Aib-Aib)  
(R)-5d  cyclo(Gly-(R)-Phe(2Me)-Gly-Aib-Phe) 
 
(S)-5d  cyclo(Gly-(S)-Phe(2Me)-Gly-Aib-Phe) 
5e         cyclo(Gly-(R,S)-Phe(2Me)-Pro-Aib-Aib)  
(R)-5e   cyclo(Gly-(R)-Phe(2Me)-Pro-Aib-Aib)  
(S)-5e   cyclo(Gly-(S)-Phe(2Me)-Pro-Aib-Aib)  
(R)-5f   cyclo(Gly-(R)-Phe(2Me)-Pro-Aib-Phe)  
(S)-5f   cyclo(Gly-(S)-Phe(2Me)-Pro-Aib-Phe)  
 
45 
64 
91 
64 
61  
55 
73 
78 
46 
47 
10 
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Table 3.  Intra- and Intermolecular H-Bonds of 5b and (R)-5f (atom numbering refers to 
Figs. 1 and 2) 
 
5b  Donor ···Acceptor N···O (Å)    N–H···O 
(°) 
(R)-5f Donor ···Acceptor N···O (Å)    N–H···O 
(°) 
N(1)–H···O(1i) (H2O) 2.817(7)      142    N(1)–H···O(11) 2.980(4)      162(4) 
N(4)–H···O(2ii) 2.956(5)      161 N(4)–H···O(8) 2.941(4)      139(4) 
N(10)–H···O(8iii) 2.967(6)      166 N(10)–H···O(42) 2.784(4)      163(3) 
N(13)–H···O(5) 3.139(6)      168 N(13)–H···O(8iv) 2.912(4)      179(3) 
N(31)–H···O(11) 2.926(6)      140 N(44)–H···O(51) 2.916(5)      154(5) 
N(34)–H···O(32iii) 3.043(5)      169 N(53)–H···O(14) 2.965(4)      150(4) 
N(40)–H···O(38ii) 2.851(6)      151   
N(43)–H···O(35) 3.011(6)      168   
O(1)–H(11)···O(41ii) 2.848(7)      174(7)   
O(1)–H(12)···O(44) 2.955(8)      144(9)   
                         
 
         Superscripted atoms refer to molecules in the following symmetry related positions: 
              i x,  –y, 1,-,2 +z;  
ii x,  –y, –  1,-,2 +z;  
iii x,  1–y, 1,-,2 +z                     
iv   1,-,2 +x, 1
1,-,2 –y, 2–z
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Table 4. Selected Torsion Angles (°) φ, ψ, and ω of the Backbone of the 
Cyclopentapeptides 5a [14c] and 5b in the Crystal  
 
 
 
 
  
ω(Gly-Aib) 
 
ω(Aib-Phe(2Me)) 
 
ω(Phe(2Me)-Aib) 
 
ω(Aib-Gly) 
 
ω(Gly-Gly) 
 
5b Molecule A 
5b Molecule B 
 
–176.2(5) 
  175.9(5) 
 
–173.9(5) 
  176.3(5) 
 
–168.0(5) 
  167.1(5) 
 
–175.1(4) 
  174.9(5) 
 
176.3(5) 
176.5(5) 
  
ω(Gly-Phe(2Me)) 
 
ω(Phe(2Me)-Aib) 
 
ω(Aib-Aib) 
 
ω(Aib-Gly) 
 
ω(Gly-Gly) 
 
5a [14c] 
 
175.8(2) 
 
165.2(3) 
 
172.1(2) 
 
177.3(3) 
 
170.8(3) 
      
  
φ(i+1) 
 
ψ(i+1) 
 
φ(i+2) 
 
ψ(i+2) 
 
β-Turn 
 
5b Molecule A 
5b Molecule B 
5a [14c] 
 
–46.9(7) 
  49.9(7) 
  56.1(4) 
 
–47.3(6) 
  45.1(6) 
  39.9(4) 
 
–119.7(6) 
  102.5(6) 
  100.0(4) 
 
  24.5(8) 
–16.6(7) 
–16.1(4) 
 
Type I 
Type I’ 
Type I’ 
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Table 5. Selected Torsion Angles (°) φ, ψ, and ω of the Backbone of the Cyclopentapeptide 
(R)-5f in the Crystal  
 
 
 
(R)-5f 
 
ω(Gly-Phe(2Me)) 
 
ω(Phe(2Me)-Pro) 
 
ω(Pro-Aib) 
 
ω(Aib-Phe) 
 
ω(Phe-Gly) 
 
Molecule A 
Molecule B 
 
–177.3(3) 
–170.7(4) 
 
–177.2(3) 
–178.2(3) 
 
–173.8(3) 
  179.3(4) 
 
–178.3(3) 
  166.3(4) 
 
–146.9(3) 
–157.0(3) 
      
  
φ(i+1) 
 
ψ(i+1) 
 
φ(i+2) 
 
ψ(i+2) 
 
Turn 
 
Molecule B 
 
–54.2(5) 
 
–40.2(5) 
 
–75.5(5) 
 
–16.1(6) 
 
β-Turn Type I/III 
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Table 6.  Crystallographic Data for Compounds 5b and (R)-5f 
______________________________________________________________________________________________ 
 
 5b  (R)-5f 
______________________________________________________________________________________________ 
Crystallized from MeO/H2O  AcOEt/MeOH/hexane 
Empirical formula C22H31N5O5.0.5H2O C30H37N5O5.CH3OH 
Formula weight 454.52 591.70 
Crystal color, habit colorless, prism  colorless, prism 
Crystal dimensions [mm] 0.20 × 0.35 × 0.40  0.35 × 0.40 × 0.52 
Temperature [K] 283(1)  173(1) 
Crystal system monoclinic  orthorhombic 
Space group Pc  P212121 
Z 4  8 
Reflections for cell determination 23  25 
2θ range for cell determination [°] 38–40 68–78 
Unit cell parameters a [Å] 15.758(2)  13.347(4) 
 b [Å] 12.595(2)  23.829(3) 
 c [Å] 12.427(2)  35.218(3) 
 β [°] 105.043(9)  90 
 V [Å3] 2381.8(5)  6500(2) 
Dx [g cm-3] 1.267  1.209 
µ(MoKα) [mm-1] 0.0922   0.0844 
Scan type ω/2θ  ω 
2θ(max) [°] 55  55 
Transmission factors (min; max) -  0.910; 1.000 
Total reflections measured 5980  15792 
Symmetry independent reflections 5730  13567 
Reflections with I > 2σ(I) 3664 8961 
Reflections used in refinement  5730   13566 
Parameters refined; restraints 714; 418  778; 42 
Final R(F)  [I > 2σ (I) reflections] 0.0553   0.0500 
 wR(F2) (all data) 0.1258   0.1355 
Weighting parameter (a; b)a) 0.0178; 2.4128  0.0727; 0 
Goodness of fit 1.069  0.958 
Final ∆max/σ 0.0001  0.001 
∆ρ (max; min) [e Å–3] 0.26; –0.28  0.25; –0.22 
______________________________________________________________________________________________ 
a) w–1 = σ2 (Fo2) + (aP)2 + bP, where P = (Fo2 + 2Fc2)/3 
 
